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Abstract of the Dissertation

Design and Testing of Novel Anthrax Vaccines Utilizing a
Tobacco Mosaic Virus Expression System

By Ryan C. McComb
Keck Graduate Institute of Applied Life Sciences: 2015

Anthrax is a potentially fatal disease caused by the bacteria Bacillus anthracis. Infection
and disease occur after spores gain entry into the body, germinate into vegetative
bacteria, and produce toxin. Bacillus anthracis spores have been engineered as
bioweapons and have been used repeatedly in warfare and terrorism to inflict casualties
in military and civilian populations. Currently, only one vaccine has been approved for
prevention of anthrax in the United States. This vaccine is an undefined product that is
difficult to produce, requires a long vaccination schedule, and is reactogenic. Efforts to
make an improved anthrax vaccine are being pursued. With recent insights into the
mechanisms by which viruses engage the immune system, novel vaccine antigens have
been designed with the hope of achieving faster and longer lasting immune responses.
These technologies, called virus nanoparticle and virus-like particle vaccines, have been
successful in the development of experimental and commercial vaccines. The research
presented is an investigation of the utilization of a Tobacco Mosaic Virus antigen display
system for inducing targeted antibody responses against defined peptides from the
anthrax toxin.
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Chapter 1-Introduction
Context of Study

Early vaccines against infectious diseases consisted of crude formulations of
attenuated pathogens that were developed based on empirical observations and methods.
As scientists developed an understanding of the biological mechanisms of the innate and
adaptive immune system, insights into the necessary characteristics of vaccine antigens
for stimulating long-lasting immunity have been accumulating. In spite of our modern
viewpoint of immunity, discovery of effective vaccines against many pathogens continue
to evade our best efforts. No vaccines exist for preventing HIV, malaria and tuberculosis,
which continue to plague low-income countries world-wide1. The most important
attribute of a vaccine is to protect individuals from specific diseases and prevent their
transmission within a society. To achieve this goal each vaccine must balance a variety of
attributes such as safety, ability to induce long lasting immunity, dosing schedule, antigen
stability, route of administration, use with adjuvants, ease of manufacturing, and cost.
These attributes must be optimized depending on the nature of the disease, the target
population, infrastructure, climate, economy and politics of a given society. Although
some vaccines are capable of balancing all these attributes, most fall short. For example,
prophylactic vaccines needed to protect children against endemic and highly contagious
diseases such as measles and chicken pox must emphasize safety, induction of long
lasting immunity, and low cost in order to maintain high vaccination rates in a
population. On the other hand, a pandemic influenza vaccine, administered to combat an
unforeseen outbreak of a highly contagious and rapidly mutating virus, may call for a
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rapid and flexible manufacturing platform in order to make large quantities of doses
available quickly while only needing to provide immunity for the duration of the
pandemic. Vaccines needed to protect against potential bioterror or biowarfare threats,
such as Smallpox and Anthrax, require a different profile of characteristics.
Countermeasures against biowarfare and bioterror attacks are an important component of
national security. They are administered primarily to military and emergency personnel
but are also stockpiled for civilian use. Ideally, these vaccines should induce immunity
quickly with few doses, be capable of rapid manufacturing, have a long shelf life, and
induce potent neutralizing antibodies that protect against high levels of infectious agents.
Many early vaccines designed to prevent a variety of diseases are still in use today and
have non-optimal characteristics that need to be improved to more effectively fulfill their
intended goals.
Statement of Problem

Anthrax is a disease caused by the gram-positive bacteria Bacillus anthracis,
which has afflicted humans and their livestock for centuries. B. anthracis forms
endospores capable of remaining viable in the soil for decades. Infection occurs when an
animal inhales, ingests, or has contact with the spores through broken skin2. Spores
germinate into vegetative bacteria and secrete a toxin that consists of three protein
molecules called Protective Antigen (PA), Edema Factor (EF) and Lethal Factor (LF). PA
functions by shuttling EF and LF into the cytosol where they exert toxic effects inside the
cell. Mortality rates for untreated cutaneous and gastrointestinal anthrax are <1% and
60% respectively. However, mortality rates of injectional and inhalational anthrax are
34% and 45% respectively even with modern medical treatment2,3. The Centers for
2

Disease Control and Prevention (CDC) have categorized B. anthracis as a “Category A”
bioterror threat for the following reason: spores can be easily disseminated in a populated
area resulting in high mortality rates that would cause extreme concern and social
disruption. Special actions are therefore required for public health preparedness against
an attack with B. anthracis4.
Historically, B. anthracis spores have been used in modern conflicts including
World War I and II, when many countries, including the U.S. and Great Britain,
developed expertise producing Anthrax weapons. More recently, the 2001 letter attacks
in which anthrax laced mail was sent to representatives in congress and news reporting
agencies in the U.S. demonstrated that B. anthracis could be used effectively as a
bioterror weapon to incite panic and inflict casualties among a civilian population. In
fact, the World Health Organization performed an assessment of a hypothetical worst
case scenario and found that an aircraft releasing 50 kg of anthrax spores over an urban
population of 5 million people would result in 250,000 casualties comprising 95,000
deaths and 125,000 severely incapacitated victims requiring treatment. A CDC model
predicted the cost of the result of an anthrax attack to be $26.2 billion per 100,000
persons exposed3. In the worst case scenario just mentioned, the financial cost alone is
estimated to be $66.5 billion.
Current treatments for B. anthracis infection can be classified into three
categories: antibiotics, antitoxins and vaccines. After confirming infection with B.
anthracis in a patient, a 60 day, intravenous administration of Penicillin, Doxycycline
and/or Ciprofloxacin is performed5. The long antibiotic treatment time is necessary since
spores may continue germinating for up to two months following initial exposure.
3

Although this treatment will kill vegetative bacilli it will not have any effect on toxin
already circulating in the blood stream, which may still result in mortality. For this
reason, the Food and Drug Administration (FDA) has approved two passive antibody
therapies that target anthrax toxin in the blood. Raxibacumab (ABthrax™) is a
monoclonal antibody (mAb) that blocks the effects of toxin while Anthrax
Immunoglobulin Intravenous (Anthrasil™) is a polyclonal antibody treatment derived
from vaccinated human donor serum. The U.S. government has purchased 65,000 doses
of Raxibacumab in a contract worth approximately $316 million putting the cost per dose
at about $4,8626,7. Only one vaccine has been approved to prevent anthrax infection and
is called Anthrax Vaccine Adsorbed (AVA) or BioThrax®. Although safe and effective,
AVA requires a long initial immunization time frame of intramuscular injections at 0, 1
and 6 months. Vaccine recipients are not considered protected until completing this initial
series. Following which, booster doses are administered at 12 and 18 months and a
maintenance dose is administered annually8. Unvaccinated individuals exposed to
anthrax, such as civilians, must develop anti-toxin antibodies quickly in order to combat
the increasing toxin load in the blood. Also, emergency and military personnel, often
under spontaneous deployment deadlines, require a more flexible vaccination schedule to
ensure they are protected in the event of an exposure. Additional limitations exist in the
way AVA is produced. For example, AVA is made from a B. anthracis culture filtrate
consisting of undefined components. Each lot of vaccine must undergo testing and
validation to show protection in guinea pigs challenged with B. anthracis spores before it
is released for human use9. This process is slow and inflexible and not ideal for producing
vaccines during an emergency scenario. Also, AVA causes local (≥10%) and systemic
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(≥5%) reactions in some individuals8, which has fostered a perception that the vaccine is
unsafe. This perception has fueled resistance against vaccine compliance among some
military personnel. In response to these shortcomings, a Department of Defense (DoD)
commissioned study in 2001 outlined goals for future anthrax vaccine development10.
This report specified product characteristics, performance standards and manufacturing
ideals. In short, a future anthrax vaccine should consist of defined components that elicit
sufficient immunity after 2-3 doses within 30 days and maintain stability for a long
period of time. In addition, this product should protect monkeys from aerosolized anthrax
for at least 1 year after initial immunization and have minimal local adverse reactions and
no severe systemic adverse reactions. Finally, this vaccine should be easily scaled up to
ensure product consistency10. Experimental anthrax vaccines utilizing new antigen design
techniques and formulations are warranted for investigation.
Aim and Scope

Many new antigen design techniques are being explored for a variety of diseases
and show promise for eliciting longer-lasting, protective immune responses with fewer
doses. One such approach is to use virus nanoparticles (VNPs) or virus-like particles
(VLPs) that display a specific antigen on their surface. VNPs are virus particles that have
either been rendered non-infectious through chemical treatment or are not infectious
because they are derived from non-animal viruses that are incapable of replication in
animal cells. VLPs are self-assembling viral capsids that do not contain a viral genome,
thus maintaining all the structural characteristics, such as size and shape, of a whole virus
without being infectious. The mammalian immune response has evolved particularly well
for responding to viral antigens. Both the size and repetitive surface organization of
5

viruses are optimal for engaging and activating naïve CD4+ T cells and B cells11. Virus
particles have an advantage over soluble proteins, like PA, for stimulating the immune
system because their size and repetitive organization makes them amenable for uptake
and processing by antigen presenting cells (APCs) which then activate naïve CD4+ T
cells. In addition, these properties of viruses make them more effective at engaging and
cross-linking B-cell receptors for subsequent stimulation and differentiation into antibody
secreting plasma cells and memory B-cells. By displaying specific antigens on the
surface of specific VNPs or VLPs through genetic modification or chemical conjugation,
it is possible to confer the favorable immunogenic properties of the underlying virus
particle onto the foreign antigen displayed on the surface11,12. This means that vulnerable,
defined antigens and epitopes from specific pathogens can be targeted for inducing high
titers of protective antibodies.
Anthrax vaccine research has been limited in its evaluation of VNP and VLP
platforms. Several studies have focused on the fusion of B. anthracis whole PA or
isolated domain IV (responsible for cellular receptor binding) to the surface of various
viral capsids. These studies have explored VLP and VNP antigen display platforms such
as flock house virus13, hepatitis B virus14,15, influenza virus16 and rabies virus17. Although
these studies show the feasibility of VNP/VLP antigen design for anthrax vaccines they
are narrow in scope with regards to the specific PA antigens they test. These studies not
only omit many potentially important neutralizing epitopes on other domains of PA but
they also include many unnecessary epitopes that do not induce neutralizing antibodies.
In addition, genetically expressing whole, foreign protein domains on various VNPs and
VLPs can be challenging due to incompatibilities in size and amino acid composition that
6

may disrupt the self-assembly of the capsid, proper folding of the antigen, or the ability
of the expression system to produce the VLP/VNP particles. Solving this problem
through in vitro chemical conjugation of VNP/VLPs to foreign antigens is expensive and
not practical from a manufacturing perspective since individual protein components
would need to be purified separately and then combined. Short, defined peptide epitopes
may be the key for overcoming many of these shortcomings. However, there are a limited
number of studies that explore defined epitope-focused vaccines with regards to anthrax
PA. More research and exploration is required to assess the feasibility of utilizing
VNP/VLP systems for anthrax vaccines.
Within the realm of VNP/VLP vaccine technology, plant viruses are an attractive
choice for displaying anthrax neutralizing antigens. Plant viruses such as Cow Pea
Mosaic Virus, Tobacco Mosaic Virus, Cucumber Mosaic Virus, Alfalfa Mosaic Virus,
Potato Virus X, Papaya Mosaic Virus and others have been investigated for their ability
to present heterologous peptides comprising neutralizing antibody epitopes and induce
the immune response in animals against viral, bacterial and protozoan pathogens18. These
viruses exist in many different shapes and sizes making them versatile in a wide range of
desired properties. Plant viruses do not replicate in animals, making them a safer platform
than attenuated or inactivated mammalian viruses that carry a risk of genetic reversion to
virulent forms or that may have been incompletely inactivated during preparation with
chemical agents. In addition, plant viruses can be made rapidly and in large quantities
making them ideal in a scenario that may require surges in vaccine demand such as
during a bioterror attack. Due to its dense array of 2,130 coat protein monomers per
virion, Tobacco Mosaic Virus (TMV) is able to present more copies of a foreign
7

antigenic peptide than all other plant viruses. Its repetitive surface structure is an
important characteristic for cross-linking receptors on naïve B cells to stimulate
differentiation into antibody secreting plasma cells. TMV is a rod-shaped virus that is 300
nm long by 18 nm wide making it an ideal size for APC uptake and subsequent T-cell
stimulation. Unlike many other viral particles, TMV coat proteins display the N- and Ctermini on the virion surface making genetic manipulation and surface expression of
foreign peptides more amenable. Finally, the utility of TMV based vaccines, in which
antigenic peptides corresponding to neutralizing antibody epitopes are fused to the coat
protein surface and administered to animals to stimulate an immune response, has been
demonstrated in various small animal disease models19. No study has been undertaken to
evaluate TMV as a potential vaccine carrier for antibody neutralizing anthrax epitopes.
The aim of this study is to investigate defined peptides, comprising antibody
epitopes and functional regions of B. anthracis Protective Antigen, displayed on Tobacco
Mosaic Virus nanoparticles for stimulating toxin neutralizing antibodies as a potential
next-generation anthrax vaccine.
Significance of the Study

Many studies have been performed to define the antibody neutralizing epitopes
and functionally important regions of anthrax PA necessary for causing cellular toxicity.
This information is needed to guide anthrax vaccine design. So far only one antibody
neutralizing epitope has been translated into a epitope focused vaccine capable of
inducing antibodies sufficient for neutralizing anthrax toxin in vivo20,21. This study will
expand the field of anthrax vaccine candidates by translating neutralizing antibody
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epitope data and functional studies into epitope focused VNP vaccines. These new
vaccine candidates could be better suited to balance the characteristics needed for
bioterror countermeasures over the current vaccine.
Overview

This thesis is broken down into five additional chapters beyond chapter 1. Chapter
2 includes the literature background and what is known about anthrax biowarfare,
pathogenesis, the state of current and experimental vaccines, and the specific antibody
neutralizing epitopes and functional vulnerabilities of PA. Chapter 3 is a breakdown of
the methods used and the approach taken to fulfill the stated aim of this research.
Chapters 4 and 5 are a presentation of the results and a discussion of their implications.
Chapter 6 explores possible future research directions and opportunities.
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Chapter 2 – Background
Anthrax as a Bioweapon

For centuries anthrax had been known to be a common disease among live-stock
and, occasionally, humans who work with live-stock or their products. The disease is
acquired through contact with spores that are present in soil. Anthrax spores have
inherent qualities that have made them attractive to individuals, organizations and
countries with malevolent interests and desires. These qualities include the ease of
undetectable dissemination in a crowded environment, the ability to cause high rates of
mortality and the ability to be produced relatively cheaply. The development of anthrax
as a biological weapon was first recorded during World War I, although limited evidence
suggests that it was actually deployed against humans22. During this conflict, German
forces were accused of attempting to contaminate the live-stock and horses of their
enemies3,23. In the Second World War, axis powers and allied forces developed
significant biological weapons programs that included anthrax. From 1932-1945, Japan
had one of the most extensive biowarfare programs of any nation and employed more
than 3,000 scientists in 5 camps that included over 150 buildings22. It is estimated that
more than 10,000 prisoners of war died as a result of experimental infection of B.
anthracis and other pathogens of interest to the Japanese. Near the end of the war, British
and American forces tested anthrax bombs on Gruinard Island (near Scotland) and at sites
in Mississippi and Utah. In fact, 5,000 bombs were produced at Camp Detrick, Maryland
that were filled with anthrax spores but never used22. After World War II, many
countries, including the U.S. and the Former Soviet Union, continued to develop their
bioweapons capabilities. In 1972, 170 nations agreed to the provisions in the Biological
10

and Toxin Weapon Convention (BTWC) which prohibits the research, development,
production or acquisition, stockpiling and use of biological agents for warfare24.
However, this agreement has no provisions for inspection or enforcement. On April 2,
1979, 96 cases of anthrax leading to 64 deaths occurred in Sverdlovsk, Russia, home to
Compound 19, a Soviet military microbiology facility. Initially the deaths were attributed
to contaminated meat but later investigations revealed that all the deaths occurred among
people working in an area down-wind of the military facility and were caused by an
accidental release of B. anthracis spores3. This accident highlights the fact that many
countries likely have disregarded the measures agreed upon at the BTWC. Most recently,
in 2001, anthrax spores were distributed in five letters mailed from New Jersey addressed
to members of the U.S. congress, journalists and news reporting agencies. The material
used in this attack was identified as the highly virulent weapons grade Ames strain which
were present at high spore concentrations, were of uniform particle size, possessed low
electrostatic charge and were treated to prevent clumping25. These features show that
capabilities continue to exist for making and distributing weaponized anthrax spores. This
act of terrorism resulted in thousands of people being treated for potential exposure, 22
confirmed cases of anthrax, of which 10 were inhalational, and five deaths. Furthermore,
this caused wide-spread anxiety and fear among the population and significant direct and
indirect costs related to clean-up, investigation and installation of mail scanning
equipment and precautionary procedures24. The history of the deliberate use of anthrax as
a bioweapon has proven that this threat must be taken seriously and that effective
treatments must be developed and available at the time of need to prevent future loss of
life.
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Anthrax Toxin Pathogenesis

Bacillus anthracis spores can gain entry into the body through abrasions in the
skin, inhalation, ingestion, or injection. Spores that gain entry into the body germinate
into vegetative bacilli and within hours secrete three toxin components called protective
antigen (PA), lethal factor (LF) and edema factor (EF). PA functions by shuttling EF and
LF into the cytosol. Once PA binds cellular receptors TEM826 and/or CMG227 and is
cleaved by cellular furin28 PA forms oligomers composed of 7 or 8 PA63 molecules. PA
oligomers are capable of binding to LF or EF molecules28,29. Toxin complexes gain entry
into the cell through clathrin mediated endocytosis and as the pH drops in the endosomal
compartment PA oligomers form pores through the endosomal membrane allowing LF
and EF to translocate to the cytosol30–32. LF is a protease that cleaves mitogen activated
protein kinase kinases (MAPKK 1 and 2) thus inhibiting cellular signaling pathways33.
EF functions as a calmodulin dependent adenylate cyclase34. Although the lethal effects
of anthrax toxin on a cellular level have been functionally identified over the past two
decades, recently the target tissue types leading to host lethality have been identified as
the cardiomyocytes and vascular smooth muscle for PA/LF toxin and hepatocytes for
PA/EF toxin35.
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Figure 1: Anthrax toxin pathogenesis against mammalian cells expressing CMG2 or TEM8 receptors.
Image used and modified with permission from Mikhail Martchenko36.

Inhalation of aerosolized anthrax spores, as would be the case in a deliberate
attack, results in the most lethal form of the disease. The incubation period of inhalational
anthrax can be as short as 1 day and as long as 9 weeks. Symptoms develop first as
influenza-like symptoms and can last hours to days. After this first phase, a severe
advanced phase occurs that is characterized by high fever, shock and respiratory distress.
In up to 50% of inhalational anthrax cases the disease spreads to the meninges resulting
in hemorrhagic meningitis. This complication increases the risk of mortality and all
individuals in the 2001 attacks that acquired this form of the disease died. Prior to 2001,
inhalational anthrax carried a mortality rate of 90%. However, improved medical care
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played an important role in cutting this mortality rate to 45% during the 2001 letter
attacks2.
Current Anthrax Vaccines

Several vaccines have been used around the world for the prevention of anthrax in
humans and animals. As early as 1881, Louis Pasteur and W.S. Greenfield developed the
first anthrax vaccine by heat treating B. anthracis cultures10. During the 1930s, less
virulent strains of anthrax were developed that lacked the genes to form a poly-γ-Dglutamic acid capsule which inhibits phagocytosis of bacilli by macrophages37. These
strains, such as the Sterne strain in the western world, STI-1 in Russia and A16R in
China, were developed as live-spore vaccines and are in use as veterinary and human
vaccines. In the west, live-spore vaccines have been discontinued in humans due to their
residual toxicity that causes necrosis at the site of injection and occasional deaths10. In the
1950s a new vaccine was introduced made from cell-free formalin treated supernatants
from the non-encapsulated Vollum strain of B. anthracis cultures that were adsorbed to
aluminum hydroxide. This vaccine was called Anthrax Vaccine Adsorbed (AVA) but has
recently been licensed by Emergent BioSolutions as BioThrax® and is the only FDA
approved vaccine for human use. AVA is indicated for use in adults aged 18-65 years at
high-risk of anthrax exposure and is administered as a primary series of intramuscular
injections at 0, 1 and 6 months followed by boosters at 12 and 18 months and annual
maintenance doses thereafter8.
There are several limitations that make AVA a less than ideal vaccine. First, the
AVA vaccine is a poorly defined protein composition that is produced in a biosafety-
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level-3 containment facility and relies entirely on animal potency and toxicity tests for
product acceptance and release38. These facts make batch-to-batch variation difficult to
control and monitor. Also, the poorly defined nature of AVA makes shelf-life testing and
estimation, which are crucial for stockpiled vaccines, difficult. Second, the immunization
schedule for AVA is long and cumbersome. From a logistical point of view, having to
administer vaccines to military or emergency personnel at frequent intervals increases the
cost of a vaccination campaign. Additionally, this lengthy schedule also may increase the
risk of non-compliance among these individuals leading to insufficient antibody levels
needed for protection against exposure. Finally, the AVA vaccine is relatively
reactogenic leading to mild erythema, soreness and swelling at the injection site lasting
for 2-3 days10,38. Although AVA is safe, the reactogenicity has led to objections by
military personnel to mandatory vaccinations and are a major reason why few recipients
receive the full immunization course38. For these reasons, considerable effort is being
made to discover and obtain approval for a new vaccine against anthrax.
Experimental Anthrax Vaccines

Many novel vaccine design strategies and production techniques are being
investigated for their application in anthrax vaccine development. It is well established
that antibodies against the PA component of anthrax toxin are necessary to provide
protection against lethality caused by B. anthracis10. For this reason, PA has been
targeted as the primary antigen in anthrax vaccine design.
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Recombinant PA Vaccines

Most of the focus on next-generation anthrax vaccines has been on recombinantly
produced PA from various expression systems. Recombinant PA (rPA) vaccines that are
the furthest along in development are those that are produced in prokaryotic systems such
as avirulent, nontoxigenic and sporulation deficient strains of B. anthracis or E. coli 39–42.
Several of these rPA vaccines have been evaluated in animal studies and human phase 1
clinical trials. Results from these studies showed that rPA with Alhydrogel® adjuvant
produced comparable Total Neutralizing Antibody (TNA) titers and anti-PA IgG titers as
AVA. Production of rPA in prokaryotic cells, such as B. anthracis, has several
advantages including expression and secretion of authentically folded protein into the
culture medium for easy purification. Also, the development of avirulent, non-toxigenic
and sporulation deficient strains of B. anthracis improves the safety profile of
manufacturing43.
Several other expression platforms have been evaluated for production of rPA
including yeast and plants. Saccharomyces cerevisiae, due to its proven record in vaccine
manufacturing and excellent safety profile, was used to evaluate rPA expression by
Merck. However, it was found that rPA could not be excreted into the culture
supernatant, required purification under denatured conditions, and could not be expressed
as full-length rPA83 due to the presence of yeast proteases44. After extraction, denatured
rPA63 did not refold into its native conformation. In spite of these undesirable expression
and purification characteristics, immunization resulted in survival of 6 of 10 (50 μg
rPA63 doses) or 8 of 9 (5 μg rPA63 doses) rabbits and 2 of 3 (50 μg rPA63 doses) or 3 of
3 (5 μg rPA63 doses) rhesus macaques following inhalational B. anthracis spore
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challenge44. Plants have also been tested to express rPA vaccines. Full length rPA83 was
transiently expressed in Nicotiana benthamiana and found to protect 8 of 8 New Zealand
White Rabbits against inhalational B. anthracis spore challenge45. Although native PA is
not glycosylated, since it is a prokaryotic protein, it does contain nine potential
glycosylation sites. Although it was shown that rPA produced in plants did exist as
various glycoforms, the added sugar residues did not impede its ability to induce toxin
neutralizing antibodies45. A phase 1 clinical trial has recently been completed for this
plant-produced rPA vaccine but results have not yet been published46.
Although rPA vaccines are a step toward a well-defined, consistent and improved
anthrax vaccine, limitations are still present. For example, as is evident in phase 1 clinical
trials, rPA vaccines do not address the need for an improved dosing schedule over the
current vaccine, AVA, and induce equivalent levels, at best, of toxin neutralizing
antibodies. In addition, rPA adsorbed to aluminum hydroxide adjuvant has been shown to
lose its ability to induce toxin neutralizing antibodies as it is stored47,48. For obvious
reasons, long-term stability is an important characteristic of a stock-piled vaccine. This
shows that rPA needs to be either re-formulated or re-designed for improved long-term
stability and immunogenicity. Other antigen design technologies are being explored as
well for developing improved anthrax vaccines.
Subunit Vaccines

Observations based on PA toxin function and delineation of neutralizing antibody
epitopes has led to the investigation of whether individual domains from PA or LF can
induce a protective antibody response. Domain IV of PA is necessary for anthrax toxin
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entry into cells through its interaction with cellular receptors (Figure 1). With this in mind,
one study used glutathione s-transferase (GST) fused to overlapping domains of PA to
vaccinate A/J mice. This study showed that all fusion proteins containing domain IV
were able to protect 5 of 5 mice from challenge with B. anthracis STI spores (103
minimum lethal dose). However, GST fusion proteins consisting of other PA domains not
including domain IV, were only able to provide partial protection49. Domain IV has been
used in many formulations and vaccine constructs for testing its potential to elicit
protective antibodies against anthrax toxin. In one study, PA domain IV was expressed
and formulated as a nano-emulsion with poly-lactide-co-glycolide (PLGA), which is an
FDA approved biopolymer that facilitates the slow release and delivery of drugs and
antigens50. Unfortunately, the domain IV-PLGA formulation was only capable of
protecting 1 of 8 Swiss Webster mice challenged with B. anthracis spores (0.4 x 108
spores/mouse) but improved median survival from 1 day (domain IV vaccinated only) to
6 days (domain IV-PLGA)50. It has been shown by others that additional protection can
be achieved when domain IV of PA is fused with domain I of LF; a region of LF
responsible for binding to PA51,52. Baillie and colleagues reported that 8 of 8 A/J mice
vaccinated with the fusion antigen survived B. anthracis spore challenge (2 x 105
cfu/mouse) compared to 7 of 8 mice vaccinated with domain IV alone51. These studies
show that individual domains can be successfully targeted for inducing protective
antibodies against anthrax.
Virus Nanoparticle and Virus-Like Particle Vaccines

One very unique class of experimental anthrax vaccines utilizes the structure and
antigenic potential of viruses as a means of improving the immunogenicity profile of PA
18

antigen targets. Observations have been made about the nature of viruses, specifically
their size and surface geometry that make them good at stimulating the immune system.
These findings have implications for vaccine development. For example, it has been
observed that antigens smaller than 10 nm (soluble proteins) are inefficiently taken up by
antigen presenting cells (APCs), such as dendritic cells and macrophages, while antigens
within 10-200 nm size range are effectively taken up11. Antigen uptake, processing and
presentation on MHC class II receptors of APCs are necessary for priming CD4+ helper
T-cells. Activated CD4+ helper T-cells provide essential stimulation to antigen activated
B-cells for antibody class switching and B-cell differentiation into long lived memory Bcells and antibody secreting plasma cells. Viruses are generally 10-300 nm in size making
them ideal for efficient uptake by APCs. Additionally, the surface geometry of an antigen
plays a vital role for inducing the adaptive immune system. For example, highly
repetitive surface structures, which are a feature of virus coat protein surfaces, have the
ability to cross-link B-cell receptors53, thus sending strong activation signals to the
antigen bound B-cells to differentiate and secrete antibodies.
Examination of some of the characteristics of native PA may explain some of the
reasons for its inability to induce rapid, long-lived protective antibody responses. For
example, the size of PA is not optimal for uptake by APCs. Also, the absence of
repetitive structural patterns, required for strong B-cell induction, may also contribute.
VNP and VLPs vaccine platforms have been developed for capitalizing on the unique
size and structural characteristics of viruses for displaying viral or non-viral antigens,
such as bacterial toxins, by fusing neutralizing peptide sequences or protein domains to
numerous types of viral capsids18.
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Various types of VNPs and VLPs have been used as a means of displaying whole
PA or single domains as experimental anthrax vaccines (Table 8 Supplemental). Among
these studies is a VLP vaccine utilizing Flock House Virus (FHV) capsid genetically
expressing the von Willebrand A domain of the anthrax toxin receptor (CMG2) on its
surface. This molecule was then loaded with whole PA83 in a repetitive array, which
remained stable through strong non-covalent interactions54. A single 10.8 μg dose
delivered subcutaneously without adjuvant protected 5 of 5 Harlan Sprague Dawley Rats
against a 10 x Minimum Lethal Dose of anthrax LT compared to 0 of 5 survivors
vaccinated with the monomeric PA83 control54. This shows that the multivalent display
of PA on a VLP surface induced a faster and more protective immune response compared
to monovalent PA83 and makes a case for the VLP vaccine paradigm. Other studies show
the feasibility of displaying PA Domain IV on various types of virus capsids and surface
proteins including HA of influenza16, Hepatitis B core15, Parvovirus B1955 and Rabies
Virus Glycoprotein17. However, it is difficult to assess their protective efficacy since
animal challenge experiments were not performed in many of these studies (Table 8
Supplemental). Nevertheless, successful VLP assembly was reported for most constructs

and PA specific antibodies were induced upon vaccination with the PA Domain IV VLPs.
VLPs and VNPs have also been tested that focus antibody responses against
shorter peptides and defined neutralizing antibody epitopes on anthrax PA. Previously
defined neutralizing regions of anthrax PA had been identified in the 2β2-2β3 loop region
comprising amino acids 302-325 of domain II56,57. Genetic expression of chimeric
Hepatitis B core particles carrying this epitope were evaluated as an epitope-focused VLP
vaccine against anthrax14,58. Initial experiments showed that these chimeric virus particles
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assembled to form VLPs. Additionally, immunization of guinea pigs with 50 μg of
Hepatitis B particles carrying the 2β2-2β3 loop without adjuvant was sufficient for
protecting 4 of 7 animals challenged with B. anthracis spores (40 x LD50) compared to 2
of 3 animal survivors that received rPA vaccination with adjuvant14. These experiments
show that defined neutralizing epitopes and functional regions of PA can be targeted on
VLPs and VNPs for candidate anthrax vaccines.
There are a number of reasons for targeting defined epitopes and shorter peptides
for vaccine design using VLPs and VNPs. In some instances, important neutralizing
epitopes and functional regions of a pathogen can be shielded from antibody responses
against native antigens. Recent work by Oscherwitz and colleagues show that the human
antibody response induced by the current AVA vaccine induces a low frequency of
antibodies against the 2β2-2β3 loop region59. In addition, other studies report that the
human antibody response induced by AVA is heavily biased toward the PA20 region,
which is not known to play an important role in toxin pathogenesis, and other nonneutralizing epitopes on PA8360,61. These studies provide support for investigating
vaccination approaches that direct the immune response toward defined neutralizing
epitopes and functional regions that play an important role in anthrax toxin pathogenesis.
More research needs to be performed to identify vulnerable defined epitopes and
functional regions of PA that can be exploited for targeted VLP and VNP vaccines.
Finally, the limited number of experimental VLP/VNP based anthrax vaccines and the
dearth of animal testing data shows that much more work needs to be performed in this
field. Certainly, VLP/VNP vaccines represent a new field for anthrax vaccine research
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and need to be explored in more detail since they may hold the key for overcoming many
of the deficiencies in current PA based vaccines.
Neutralizing Antibody and Functional Epitope Mapping of PA

A thorough mapping of the neutralizing antibody epitopes and functional regions
of the PA toxin is an essential first step for VLP/VNP antigen design for experimental
anthrax vaccines. The PA molecule is an 83 kD protein comprised of four protein
domains. After binding to the cellular receptor, PA83 undergoes cleavage by a cellular
furin to release a 20 kD fragment from domain I exposing the ligand (LF/EF) binding
sites and allowing for the receptor bound PA63 to oligomerize with other PA63
molecules (Figure 1). Domain I is thus broken into PA20, which has no known function at
this point in time, and Domain I’, which remains attached to the PA63 molecule.
Monoclonal neutralizing antibodies have been used to elucidate vulnerable epitopes of
the PA molecule. In addition, amino acids and sequences critical for the function of PA
have been discovered through mutagenesis studies and crystal structure determination.
Together this information helps define the regions of the PA molecule that are of interest
for mounting a focused countermeasure for disrupting the toxic effect of anthrax LT.
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Domain

Function (Experimental Validation)

Implicated Amino Acids

Ref.

PA20

Furin Cleavage (Deletion Mutant)

164-167

62

I'

LF/EF Binding (Alanine Scanning)

178, 197, 200, 205, 207,
210, 214

63

I’

PA Inhibition by at least 100-fold (Point
Mutations)

210, 225, 240, 245

64

II

Endosomal Pore Formation and LF/EF
Translocation

302-325

65–68

II

Exhibited Dominant-Negative Phenotype
when mixed with wild-type PA

364, 380, 382, 393, 397,
399, 411, 422, 425, 427

64,69,70

III

Blocked Oligomer Formation (Point
Mutations)

512, 514, 520

64,71

IV

Receptor Binding Loops (Crystal Structure) 654-662, 681-688, 712-714

65,72

IV

PA Inhibition by at least 100-fold (Point
Mutations)

656, 657, 665, 682, 683,
687

64

IV

Receptor Binding (Point Mutations)

679-693

73,74

Table 1: Functional mapping of Anthrax PA toxin
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Epitope
Neutralizing Neutralizing
Inhibited Function
Ref.
Location
In Vitro
In Vivo

Domain

mAb

PA20

47F12

95-106

Furin Cleavage

Yes

not tested

75

PA20

7.5G

156-170

Furin Cleavage

Yes

No

76,77

PA20

PA4 AP

162-180

Furin Cleavage

Yes

No

78

I’

19D9

196-210

Not Defined

Yes

Not Tested

76

I’

20G7

196-210

Not Defined

No

Not Tested

76

I’

PA6 AP

232-247

Not Defined

Yes

Partially

78

II

5E12, 2A8,
5E1

312-315

Endosomal Pore
Formation

Yes

Not Tested

56

II

2H9, 16A12 312-326

Endosomal Pore
Formation

No

Not Tested

76

II

F20G75, -76,
311-315
-77

Endosomal Pore
Formation

Yes

Not Tested

57

II

48.3

412-419

Furin Cleavage

Yes

Yes

79

III

2-A7

532-543

Not Defined

No

No

80

III

2D3, 2D5,
10D2

581-601

LF/EF Binding

Yes

No

81

IV

3B6

671-721

Receptor Binding

Yes

Yes

82

IV

14B7

684-688

Receptor Binding

Yes

Yes

82

IV

35PA83

686-694

Receptor Binding

Yes

Yes

83

IV

1-F1

692-703

Receptor Binding

Yes

Partially

80

IV

2-B12

716-727

Receptor Binding

Yes

Partially

80

IV

PA12 AP

628-637

Not Defined

Yes

Partially

78

Table 2: Monoclonal antibody binding and inhibition of Anthrax PA toxin
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PA20

Although the PA20 region is not known to have a functionally important role in
anthrax toxin pathogenesis, neutralizing antibodies targeting this domain have been
identified. The monoclonal antibody 47F12, which was isolated from a human donor
vaccinated with AVA, showed the ability to neutralize LT in vitro75. Through
experiments with radiolabeled PA83 it was determined that 47F12 neutralizes through
inhibition of furin cleavage. Analysis of 47F12 binding against a yeast library displaying
randomly mutated PA20 on its surface found that binding was dependent on the fidelity
of the amino acids corresponding to E95, N98, A100, N104, and I106 of PA20. In a separate
study, a screen of AVA vaccinated donor serum tested against overlapping peptides of
PA identified N102-Q115 as an epitope that bound 5/6 donor samples associated with high
neutralization of LT as determined in an in vitro cellular assay with RAW 264.7
macrophages78. This shows that antibodies directed against this region contribute to
neutralization, but it is unknown whether they are sufficient on their own for providing
protection against anthrax toxin.
The sequence 164RKKR167 that spans the interface between PA20 and PA63 is the
furin cleavage site68. It has been shown that PA variants with a deletion of residues 163168 are insensitive to furin cleavage and are non-toxic when administered with LF in
cellular assays and in rats62. The monoclonal antibody 7.5G was isolated from mice
immunized with PA83 and shown to recognize the sequence between L156 and S170,
which overlaps this site76,77. However, it is unclear from the data whether this antibody
can inhibit furin cleavage77. When purified and administered to mice 24 hours prior to LT
challenge, it was found that 1 mg of 7.5G was needed to prolong the survival of mice
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challenged with 100 μg of LT by 3 days. Furthermore, when the peptide epitope of 7.5G
was synthesized as a Multiple Antigenic Peptide (MAP) and administered to mice with
Complete Freund’s Adjuvant (CFA), it was claimed that sera samples from vaccinated
animals “moderately” protected J774.A macrophages from toxin challenge76. Since the
mice were not challenged with toxin, however, it is impossible to know if the antibodies
induced by vaccination were sufficient for in vivo protection. In another study, human
antibodies directed against the sequence between N162 and N180 of PA (designated as site
PA4 in this study) were affinity purified from AVA vaccinated donors and tested for their
ability to neutralize LT in vitro and in vivo78. This study showed that furin cleavage site
directed antibodies protected 70% of RAW 264.7 macrophages after treatment with LT
but only 1 of 10 A/J mice survived challenged with 3 x LD50 LT after treatment with 30
μg of affinity purified PA4 specific antibodies78. It appears that, although furin cleavage
is an attractive target for focused therapies from a functional standpoint, there are limited
levels of protection that can be achieved with antibodies directed against this epitope.
Domain I’

Domain I’ is the remainder of domain I after PA20 is cleaved by furin. A number
of antibody epitopes have been mapped to this domain and correspond with functionally
important amino acids sequences identified using other methods. For example, point
mutations introduced into PA domain I’ showed that replacement of any of seven
residues (R178, K197, R200, P205, I207, I210 and K214) with alanine almost completely
eliminated LF/EF binding to PA63. Analysis of the location of these seven residues in
their 3-Dimensional conformation on the crystal structure of the PA oligomer reveals that
the LF/EF binding site spans two PA molecules. A separate study showed that two
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murine antibodies, 19D9 and 20G7, bind the peptide sequence from V196 to I210 that
include many of these vulnerable amino acids associated with LF/EF ligand binding76.
Interestingly, 19D9 (IgG) is neutralizing at 1 μg/mL against LT in cellular assays while
20G7 (IgM) is not neutralizing at concentrations up to 50 μg/mL. The peptide sequence
was synthesized as a MAP and used to immunize mice in the same manner as discussed
above with the 7.5G peptide epitope. Neutralizing titers of 1:800 were observed with
from serum of vaccinated animals in a cellular LT cytotoxicity assay but no in vivo
survival data was reported. Finally, Crowe and colleagues report that sera from AVA
vaccinated human donors reacted with the peptide Y192 to P205 in a solid-phase epitope
mapping experiment, but no neutralization assays or toxin survival experiments in
animals were performed78. These studies show that antibodies targeting the LF/EF
binding site of PA are likely critical for toxin neutralization and support including this as
a potential vaccine target. However, the fact that the LF/EF binding site spans two PA
molecules in the oligomer may require an antigen mimic that closely resembles its native
conformational structure.
Another region with functional significance in domain I’ was found that included
amino acids I210, K225, T240, and K245. Cysteine substitutions at any of these 4 amino acids
resulted in the inhibition of PA activity by at least 100-fold64. Additionally, antibodies
directed against the epitope P232 to V247, which contain two of these residues, were found
in 4 of 6 serum samples from AVA vaccinated human donors with high neutralizing
serum titers78. Affinity purified antibodies directed against P232 to V247 (designated as
PA6 in this study) were tested against LT and shown to provide 50% protection of RAW
264.7 cells. Furthermore, 30 μg of these affinity purified PA6 specific antibodies were
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shown to protect 3 of 10 mice challenged with 3 x LD50 LT78. Although this sequence is
near the LF/EF binding site it is unclear what effect inhibition of this epitope has on the
normal function of PA. The proximity of this sequence to the LF/EF binding site and its
ability to partially protect cells and mice from anthrax LT warrants further investigation
into its potential usefulness as a vaccine antigen target.
Domain II

Neutralizing antibodies with epitopes that overlap known functional regions also
exist in domain II of PA. The 2β2-2β3 loop (E302 to S325), which contains a chymotrypsin
site (F313 to F314), has been shown to be involved in translocating LF/EF to the cytosol84.
Determination of the crystal structure of PA and further experimentation with cysteine
substitutions along amino acids 302-325 provide strong evidence that 2β2-2β3 loops from
individual PA molecules in the heptamer complex combine to form a 14-stranded
transmembrane β-barrel induced by the low-pH of the endosome65–67. Furthermore, when
this loop was substituted with a homologous membrane-inserting loop from iota-b toxin
of Clostridium perfringens and mixed with wild-type PA in equimolar ratios, a dominantnegative phenotype was observed in which LT killing was completely inhibited in
cellular studies and in rats68. These studies provide strong evidence that this amino acid
sequence is necessary for LF/EF toxicity mediated through PA. Various studies report
antibodies that bind PA at this location but differ in effectiveness for neutralizing anthrax
LT. Murine monoclonal antibodies (5E12, 2A8 and 5E1) mapped to the chymotrypsin
sequence (312-315) and were shown to inhibit chymotrypsin cleavage of PA into 47kD
and 37kD fragments56. Although the neutralization capacity of antibodies 5E12, 2A8 and
5E1 is claimed, no percent survival values are reported from cellular assays. In another
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report, antibodies 2H9 and 16A12 mapped to the region between amino acids 312-326
and were not shown to be neutralizing76. However, Gubbins and colleagues report the
discovery of three antibodies (F20G75, F20G76 and F20G77) that recognize the
consensus sequence 311ASFFD315 within the 2β2-2β3 loop57. Cellular assays were
performed in which dilutions of each antibody were incubated with PA/LF toxin for 1
hour at 37° C prior to addition onto J774.A macrophages. They report that cells were
protected to values between 90-100% at concentrations as low as 12.5, 11.8 and 16.0
ng/mL respectively. Interestingly, when the assay format was changed such that PA was
allowed to incubate with cells prior to the addition of LF and antibodies, 90% protection
was achieved only with higher (1-10 μg/mL) concentrations. This observation provides
evidence that this epitope is inaccessible once PA has bound to the cellular membrane.
The disagreement between various neutralization capabilities of antibodies that bind this
region are possibly indicative of specific affinity/avidity thresholds, antibody class type
requirements, and epitope fine tuning in order to achieve effective neutralization.
Functional analysis and monoclonal antibody neutralization studies give a rational
basis behind targeting the 2β2-2β3 loop in a vaccine formulation. Based on this data,
there have been reports of vaccines that target the epitope comprising amino acids G305 to
S319. The first attempt at targeting this epitope was performed by inserting this amino acid
sequence onto the self-assembling Hepatitis B core protein scaffold as described
above14,58. The second attempt was made by creating a synthetic peptide constructed as a
MAP on a lysine backbone. This vaccine was shown to induce protective antibodies in
vitro and in vivo20,85. Seven New Zealand White Rabbits were immunized initially with
250 μg of MAP comprising the 305-319 sequence from PA and a helper T-cell epitope
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from Plasmodium falciparum in CFA followed by four 125 μg vaccine boosts in
Incomplete Freund’s Adjuvant (IFA) at 2 week intervals. Vaccinated rabbits were
challenged through the inhalational route with 200 x LD50 B. anthracis Ames strain
spores. Seven out of seven MAP-305-319 vaccinated rabbits survived spore challenge
compared to 7/7, 0/6 and 0/6 PA vaccinated, MAP control vaccinated or naïve control
rabbits respectively85. The 2β2-2β3 loop has a necessary role in anthrax toxin
pathogenesis and inhibition of this site through antibodies induced by an epitope focused
vaccine is sufficient to provide protection against the lethal effects of virulent anthrax
spores.
Mutational analysis and monoclonal antibody neutralization has uncovered a
second region in domain II necessary for anthrax toxin pathogenesis. PA mutants with
single amino acid substitutions in the region of amino acids S337 to N458 were found to
reduce LT toxicity by at least 100-fold in a cellular toxicity assay64. More specifically,
cysteine substitutions at I364, T380, S382, T393, N399, Y411, N422 and changes at D425K, K397D
and F427A exhibited a dominant-negative phenotype in which PA containing any of these
mutations mixed with wild-type PA inhibited LT killing of cells64,69,70. Further analysis
showed that these PA mutants all retained the ability to bind cellular receptors, form
heptamers, and bind LF but were deficient in endosomal pore formation and LF
translocation to the cytosol64. Only one neutralizing monoclonal antibody has been
mapped to the region between I364 and F427 and is the IgG1 mAb 48.3 that recognizes an
epitope consisting of S412 to I41979. Unexpectedly, the mechanism by which 48.3 provides
protection is through inhibition of the furin cleavage step in PA toxicity, thus preventing
the formation of PA63 required for oligomerization and ligand binding. There is no
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obvious connection why this epitope would inhibit furin cleavage based on its location
since analysis of the crystal structure shows that the furin cleavage site and amino acids
412-419 are not co-localized and are even located on opposite faces of the PA molecule.
It could be that this site is required for furin recognition and stabilization for subsequent
cleavage at the 164RKKR167 target site. Protective efficacy of mAb 48.3 was shown in
mice challenged with a sub-cutaneous infection of toxin producing Sterne strain B.
anthracis spores. In this study, 6/8 and 2/8 mice treated with 100 μg or 10 μg of antibody
respectively, survived challenge of a 10 x LD50 dose of spores79. Further evidence for the
importance of this region is found in the fact that human serum antibodies from 4/6 AVA
vaccinated donors cross-reacted with peptides corresponding to amino acids 406-41978.
These studies suggest that amino acids located between I364 and F427 seem to play a
primary functional role in anthrax toxin pathogenesis and that antibody epitopes within
this region are an important component of a protective immune response. This region,
therefore, represents another potential vaccine target for epitope focused therapies.
Domain III

From a functional standpoint, domain III appears to be involved with PA
oligomer formation. For example, it is possible to induce PA oligomer assembly in vitro
by adding the N terminal fragment of LF to a solution of PA6371. Insertion of missense
point mutations at amino acids D512, L514, and D520 blocked detection of oligomer
assembly suggesting that these residues within domain III are important in this step of
anthrax toxin pathogenesis71. In a separate study, a point mutation at E515 inhibited the
activity of PA by 100-fold in cellular toxicity assays64. From the crystal structure it is
apparent that this region of PA forms a loop that is in close contact with amino acids P173
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to A258 of domain I’ in a neighboring PA monomer stabilizing the oligomer complex72.
Although functionally important, no neutralizing mAbs have been reported that bind this
region of PA.
It has been determined that antibodies directed against domain III contribute to
neutralization of LT in vitro. However, none of these antibodies appear to bind regions
that are correlated with functional importance as described previously. For example,
recombinantly expressed and purified domain III of PA competes with toxin neutralizing
serum from PA vaccinated rabbits, non-human primates and humans86. This study did not
identify epitopes on domain III that were associated with this competitive inhibitory
effect. In another study, antibodies from mouse hybridomas (2D3, 2D5 and 10D2) were
discovered that bind between I581 and N601, which spans the end of domain III and the
beginning of domain IV81. Interestingly, the data suggests that the mechanism by which
2D3, 2D5 and 10D2 confer protection seems to be by inhibition of LF binding to PA
indicating that this region interacts closely with domain I’. Although these mAbs showed
neutralization of LT in a cellular assay (2D3-0.1 μg/mL, 2D5-0.03 μg/mL, 10D20.1μg/mL to protect 80% of J774.A cells), they were not capable of protecting Fisher 344
Rats from death. Rats challenged with 13 x LD50 LT incubated with up to 1.7 mg IgG
from ascites for 1 hour only delayed death by 18 hours (2D3 and 2D5) or 0 hours (10D2
and IgG negative control)81,82. These studies show that mAbs targeting discrete epitopes
on domain III do contribute to a neutralizing response against LT, but are not sufficient
on their own to neutralize LT in vivo. This fact is supported by a number of other studies
that report mAbs that bind domain III but on their own are incapable of neutralizing
anthrax LT. Antibody 2-A7, that was found to bind amino acids G532 to Q543, did not
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protect mice against LT challenge80. Fisher 344 Rats challenged with LT and
administered domain III binding antibody 8A7 at a 1:1 antibody to PA molar ratio also all
died87. However, when 9 μg of 8A7 was administered in combination with 9 μg of 2A6
(an antibody whose epitope is undetermined, but also was unable to protect Fisher 344
Rats against LT challenge on its own) 5/5 rats survived a lethal dose of anthrax toxin.
These data support the conclusion that domain III antibodies may need to work in concert
with antibodies against other regions on PA in order to provide sufficient protection
against anthrax toxin.
Domain IV

Domain IV contains important functional sequences for epitope targeted
therapeutics. As discussed above, numerous studies have shown that antibodies directed
solely against domain IV are sufficient for neutralizing anthrax toxin. Crystal structure
analysis of PA bound to CMG2 shows that this interaction is primarily attributed to
amino acids found in three loops of domain IV comprising amino acids E654 to M662, Y681
to Y688, and E712 to G714 and one loop from domain II65,72. Consistent with the prediction
that these amino acids have important functional activity due to their role in binding host
cellular receptors is the observation that cysteine substitutions at residues I656, N657, I665,
N682, D683, and L687 inhibit PA activity by at least 100-fold64. An additional study shows
that mutations in the loop containing amino acids K679 to N693 were most detrimental to
PA toxicity while mutations between E704 to K722 allowed PA to retain its toxicity73.
Interestingly, it was found that an alanine substitution at D683 had the most significant
effect on PA toxicity and binding. PA molecules carrying this mutation showed a 1000fold reduction in cellular toxicity74.
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Some of the most potent mAbs for neutralizing PA have the ability to block
binding to host cellular receptors. Neutralizing murine antibodies 3B6 (926 μg) and 14B7
(23 μg) protected 4/4 Fisher 344 Rats challenged with anthrax LT82. These antibodies
were subsequently shown to bind between amino acids D671 and I72181. Further studies
with alanine substitutions at specific residues in the PA binding domain showed that
amino acids K684, L685, L687 and Y688 were critical for 14B7 recognition and
neutralization74. A high affinity (KD=3.4 nM), highly neutralizing (50% inhibitory
concentration, 5.6 nM) Fab isolated from an immunized macaque designated as 35PA83
was found to also bind between P686 and Y69483. Correlation between PA neutralization
with antibodies 14B7 and 35PA83 with mutagenesis studies show that the receptor
binding loop between K679 to N693 is an important target for anthrax toxin
countermeasures.
Two additional murine antibodies were found to bind regions of domain IV that
inhibit PA binding to CMG2 and show both in vitro and in vivo neutralization efficacy80.
Monoclonal antibodies 1-F1 and 2-B12 bind to linear epitopes located between P692 to
K703 and T716 to F727 respectively. High affinities (1-F1, 1.7 nM and 2-B12, 2.0 nM) and
in vitro neutralization of LT (1-F1 at 7 ng/mL protects 100% J774.A macrophages while
2-B12 at >4 ng/mL protects 90% of J774.A macrophages) were reported. Additionally,
550 μg/mouse of 1-F1 or 2-B12 protected 2/5 and 3/5 BALB/c mice challenged with a
lethal dose of anthrax LT respectively. Given the close proximity of these epitopes to the
functionally essential loop between K679 to N693, it is not surprising that these antibodies
have some ability to inhibit anthrax toxin. It appears though, that these antibodies are not
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as effective at blocking toxin entry as 14B7 and 35PA83 that recognized the loop between
amino acids 679 and 693.
Another epitope associated with domain IV was found to exist between L628 and
K637 (designated as epitope PA12)78. Antibodies against this peptide sequence were
affinity purified from AVA vaccinated human serum and a 30 μg/mouse dose was found
to protect 6/10 mice from 3 x LD50 anthrax LT challenge. The specific mode of inhibition
for these antibodies was not determined. Domain IV is a crucial target for anthrax toxin
therapies based on PA functional studies, crystal structure analysis and the potency by
which antibodies targeting this region protect cells and animals against anthrax toxin.
In summary, PA contains many functional regions that can be targeted for epitope
focused therapeutics. These regions come from all four domains of the PA molecule and
include antibody epitopes and functional regions that, if blocked, are sufficient by
themselves for anthrax toxin neutralization. On the other hand, PA contains many more
partially neutralizing epitopes and functional sites of inhibition. These studies suggest
that blocking multiple regions of the PA toxin simultaneously will likely provide a more
complete protection. An epitope defined vaccine will, more likely than not, need to
include a variety antigen targets to induce complete immunity against anthrax.
Rationally Designed Vaccines

Functional mapping, crystal structure analysis and identification of the
neutralizing antibody epitopes on PA provides a starting point whereby vaccine antigens
can be rationally designed to induce protective immunity against anthrax infection. This
approach to vaccination has been termed “rational” or “structural” vaccination since the
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starting points for design of vaccine antigens are neutralizing antibody epitopes and
functional regions of the pathogen88,89. Such an approach is currently being considered
for a number of intractable vaccine targets such as HIV90, Hepatitis C91 and Influenza92
that have highly complex surface antigens that mutate rapidly. The strength in this
approach lies in the fact that many native antigens are not adapted for stable storage,
production or elicitation of neutralizing antibodies to conserved regions of complex
antigens89. In the case of anthrax, PA requires optimization for improved storage and a
well-defined vaccine product that elicits longer-lasting immunity with fewer doses. A
rational approach to anthrax vaccination may help achieve these goals. In the following
chapters, a rational approach for antigen design against anthrax toxin is investigated
using the virus nanoparticle TMV.

36

Chapter 3 – Research Approach and Methods
The goal of this chapter is to introduce the research strategy and methods for
expressing and testing defined epitope vaccines for prevention of anthrax toxin induced
mortality. The stages of this research are outlined in Figure 2. First, antigen targets from
PA toxin of B. anthracis were selected that are associated with either important required
functions for toxin binding and cellular entry or identified through antibody screening
studies. Antigen selection was followed by gene synthesis and cloning into TMV
expression vectors. This was followed by plant inoculation with recombinant viral RNA,
screening of inoculated plant tissue for assembled virions, and purification/analysis of
modified TMV proteins or genomes. Following successful purification and confirmation
of the presence of the PA peptide addition, TMV coat proteins were screened for crossreactivity with anti-PA antibody raised against the native PA83 molecule using Western
Blot and ELISA. TMV coat protein-PA peptide fusions that successfully passed these
screening steps were selected for in vivo studies in mice to determine if they could induce
cross-reactive, toxin neutralizing antibodies that protected animals from B. anthracis
spore challenge.
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Figure 2: Research approach for testing TMV-PA peptide fusion vaccine candidates
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Selection and Design of PA Epitopes Displayed on TMV

Identification of antibody epitopes have been reported previously and were
performed by screening human AVA vaccinated donor serum78 or PA vaccinated mouse
serum76 against overlapping peptides spanning the entire amino acid sequence of PA. The
minimally defined epitopes from these reports formed the majority of the immunogenic
PA peptide sequences in this study. Sequences were also selected by analysis of the
crystal structure of PA interacting with cellular receptor CMG265,72 and from reports of a
vulnerable linear epitope located in the 2β2-2β3 region of domain II identified from
neutralizing mAbs57 and peptide focused vaccines14,20. The complete list of epitopes
selected for this study is described in Table 3. These sequences make up approximately
32% of the amino acids comprising B. anthracis PA.
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Epitope PA amino acid
Epitope Sequence
#
(#)
1
66-77 (12)
SGFIKVKKSDEY*
2
102-115 (14)
NSNKIRLEKGRLYQ*
3
124-143 (20) NPTEKGLDFKLYWTDSQNKK*
4
152-171 (20) QLPELKQKSSNSRKKRSTSA*
5
192-205 (14)
YTVDVKNKRTFLSP*
6
232-247 (16)
PYSDFEKVTGRIDKNV*
7
284-297 (14)
SETRTISKNTSTSR*

Peptide Properties
(pI/M.W.)
8.16/1.40
10.28/1.72
8.38/2.42
11.17/2.27
9.70/1.67
6.53/1.87
10.83/1.57

PA
Domain
I
I
I
I/I'
I'
I'
II

8

316-333 (18)

IGGSVSAGFSNSNSSTVA*

5.52/1.64

II

9
10
11
12
13
14

360-369 (10)
406-419 (14)
556-567 (12)
628-637 (10)
724-733 (10)
676-693 (18)

LNANIRYVNT*
APNNYYPSKNLAPI*
QQTSQNIKNQLA*
LLNIDKDIRK*
ILIFSKKGYE*
IDFKKYNDKLPLYISNPN*

8.75/1.18
8.54/1.56
8.75/1.37
8.59/1.23
8.50/1.20
8.38/2.18

II
II
III
IV
IV
IV

15

304-319 (16)

HGNAEVHASFFDIGGS*

5.15/1.64

II

16

196-210 (15)

VKNKRTFLSPWISNI*

11.17/1.80

I

Proposed Function
PA20
PA20/Furin Cleavage
PA20
Furin Cleavage
LF/EF Binding
Not Defined
Not Defined
Endosomal Pore – LF/EF
Translocation
Not Defined
Furin Cleavage
Not Defined
Not Defined
Receptor Binding
Receptor Binding
Endosomal Pore – LF/EF
Translocation
Furin Cleavage

*Ref.
78
75,78
78
62,76–78
63,76,78
64,78
78
65–68,76,78
64,69,70,78
64,69,70,78,79
78
78
78,80
64,65,72,82,83
14,20,56,57,65–
68,84
63,64,76,78

Table 3: Defined peptide epitopes from PA toxin selected for vaccine targets against Anthrax. Amino acid properties: Positively Charged – R, H, K;
Negatively Charged – D, E; Polar (hydrophilic) – G, S, T, N, Q, C; Non-polar (hydrophobic) – A, V, I, L, P, M, F, W, Y. Isoelectric point (pI), Molecular
Weight in kD (M.W.). *References include structure/function experiments and antibody mapping studies that cross-reference any amino acids included in the
selected epitope.
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Tobacco Mosaic Virus was chosen as an immunogenic, virus nanoparticle for
presentation of peptide epitopes from PA. TMV is a rod-shaped virus that is
approximately 18 nm x 300 nm comprising an RNA genome encapsidated by 2,130 selfassembling coat protein monomers. The size of TMV thus allows efficient uptake by
antigen presenting cells for CD4+ T-cell priming and the repetitive surface structure,
displaying 2,130 copies of immunogenic peptide19, is potentially ideal for potent crosslinking of B-cell receptors. The 17.6 kD coat protein monomer is composed of 159 amino
acids and can accommodate the surface expression of heterologous amino acid insertions
on the N-terminus, C- terminus, or the surface exposed loop at amino acids 59-65 making
genetic manipulation and display of foreign amino acids easier93. Since TMV is a plant
virus it grows without the need of animal serum or mammalian cell-lines that could
harbor pathogenic organisms thus making it safe to manufacture. Plants expressing TMV
can be grown in Good Manufacturing Practice (GMP) environments and scaled up with
ease, making this system good for producing a consistent, well defined vaccine product94.
These properties make TMV a good candidate for testing vaccine targets against B.
anthracis PA.
Cloning and Expression of Recombinant TMV Displaying PA Peptides
Expression Vectors

Various TMV expression technologies have been developed for expression of
heterologous proteins in plants. Previously, the DN15-GFP-6H (Figure 11 Supplemental)
plasmid was designed by Large Scale Biology to express a heterologous protein (GFP)
with a 6-His tag through a systemic TMV infection initiated with T7 in vitro transcribed
RNA rubbed directly onto plant leaves. The presence of the Tobacco Mild Green Mosaic
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Virus (TMGMV) coat protein gene allows for systemic movement of the virus through
the phloem tissue after inoculation. This system most closely resembles the natural, wildtype TMV infection in plants and does not expose the TMV RNA genome to the nuclear
environment of the plant cell. In contrast, the pJLTurbo95 plasmid retains the TMV RNADependent RNA Polymerase and Movement Protein genes but includes PacI, AvrII and
NotI cloning sites in place of the Coat Protein gene allowing for heterologous proteins to
be cloned and expressed (Figure 12 Supplemental). The pJLTurbo vector is under the control
of duplicated 35S promoters of the Cauliflower Mosaic Virus in an Agrobacterium
tumefaciens/Escherichia coli binary vector. A. tumefaciens transformed with recombinant
pJLTurbo plasmid grown under Kanamycin, Rifampicin, and Gentamycin antibiotic
selective pressure and delivered to leaves of a susceptible host plant through syringe or
vacuum infiltration will initiate a TMV infection coupled to heterologous protein
expression. TMV coding genes are introduced to the nucleus via A. tumefaciens mediated
transformation and transcribed into RNA that is exported to the cytosol and translated.
Since the RNA-Dependent-RNA Polymerase is translated, viral RNA, along with
heterologous protein RNA, can be replicated directly in the cytosol. The TMV movement
protein allows for cell-to-cell movement of the TMV replication complex thus allowing
for further takeover of plant cell protein synthesis machinery. However, since pJLTurbo
lacks the coat protein gene, RNA is not coated and, therefore, cannot spread through the
phloem tissue to systemically infect the plant. The use of whole plant vacuum infiltration
obviates the need for the virus to move through the phloem since every leaf is inoculated
simultaneously with A. tumefaciens culture under vacuum.
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Assessing the capacity of TMV coat protein to accommodate heterologous
peptide insertions derived from B. anthracis PA was simplified by using the DN15-TCS
plasmid. DN15-TCS is a vector derived from DN15-GFP-6H and pJLTurbo95. The
DN15-GFP-6H plasmid was digested with KpnI-HF and PacI to remove the GFP-6 His
Tag, TMV U1 CP 3’ UTR, TMGMV CP and TMGMV CP 3’ UTR. A PCR amplified
fragment of the 244 base pair stretch of pJLTurbo’s cloning region, containing the
Pac1/AvrII/NotI sites and the TMV CP 3’ UTR, was similarly digested with KpnI-HF
and PacI and ligated into the DN15 backbone to produce DN15-Turbo Cloning Site
(TCS) (Figure 13 Supplemental). The primers used for amplification of the 244 base pair
stretch were Turbo Cloning Site Forward, 5’ TCT TAC AGT ATC ACT ACT CCA TCT
C 3’, and Turbo Cloning Site Reverse, 5’ ACC ATG ATT ACG CCA AGC TT 3’. The
DN15-TCS vector resembles pJLTurbo except for the fact that the TMV genome and
heterologous cloning sites are under the control of the T7 promoter instead of the 35S
Cauliflower Mosaic Virus promoters. In addition, DN15-TCS contains a simple E. coli
competent replication backbone, as opposed to the pJLTurbo A. tumefaciens/E. coli
binary vector backbone, making genetic manipulations easier due to its smaller size. The
DN15-TCS vector was constructed for two reasons. First, coat protein-PA peptide fusion
constructs could be cloned and expressed in plants more quickly than through A.
tumefaciens mediated transformation using pJLTurbo. After constructs were cloned into
the DN15-TCS vector, infectious in vitro transcribed RNA could be made within hours
and used to infect plants to test expression and virus stability. The same process takes 1
week using A. tumefaciens transformed with pJLTurbo/TMV Coat Protein-PA constructs.
Second, inoculation of plant cells using in vitro transcribed DN15-TCS RNA resembles a

43

more natural infection route through direct viral replication in the plant cell cytosol
without introduction of TMV RNA into the plant cell nucleus. At least one report
describes cryptic intron splice sites within the TMV genome that directly affects
heterologous protein yields96 when using non-optimized A. tumefaciens based TMV
expression vectors. Since in vitro transcribed RNA is not introduced to the nucleus
through this route of infection, any specific problems related to nuclear RNA processing
are bypassed. For these reasons, DN15-TCS was used to initially screen coat protein-PA
peptide expression and virus assembly.
Recombinant TMV Expression and Virus Purification

TMV coat protein U1 strain genes were synthesized (Genewiz Inc.) with coding
sequences for PA1-PA16 peptide epitopes (Table 3), optimized for TMV codon
specificity, genetically fused to the C-terminus. The C-terminus of TMV coat protein was
chosen for fusion since more published reports have used this region successfully.
Modified coat protein genes were cloned with AvrII and NotI-HF (New England Biolabs)
into the pDN15-TCS vector which contains the TMV genome, except the coat protein
gene, under T7 promoter transcriptional control. T7 transcription reactions (20 μL
volumes) were set up using 500 ng vector templates with the mMessage mMachine T7
Transcription Kit (Life Technologies) according to the manufacturer’s directions and
incubated for 2 hours at 37°C. Reactions were then mixed with 250 μL room temperature
FES (100 mM Glycine, 22.4 mM Sodium Pyrophosphate, 45.8 mM Potassium Phosphate
Dibasic, 10% Bentonite (w/v), 10% Celite® (w/v), autoclaved 121°C for 20 minutes) and
spread over 2 leaves on three Nicotiana benthamiana plants, approximately 3 months old,
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with a gloved finger and incubated at 24°C/16 hours light and 21°C/8 hours dark for 3
weeks.
Modified viruses were extracted from leaf tissue as follows. Leaves showing
symptoms of virus infection (yellowing, curling and crinkled leaves) were removed and
weighed. Tissue was homogenized with a mortar and pestle in 4-volumes (4x mL
buffer/g leaf tissue) extraction buffer (50 mM Sodium Acetate, 0.1% Sodium
Metabisulfite (w/v), 0.01% Beta-Mercaptoethanol (w/v), pH 5.0) and filtered through 2layers of cheesecloth. Green extract was heat shocked for 5 minutes at 50°C and
centrifuged for 25 minutes at 8,000 x gravity (G) at 12°C. The supernatant was measured
and poured into a new container where 40% PEG 8,000 and 5M NaCl was added to make
a final concentration of 4% PEG and 0.68 M NaCl respectively. The mixture was chilled
at 4°C on ice for 1 hour and then centrifuged at 15,000 x G for 25 minutes at 4°C.
Supernatants were carefully poured off and pellets were resuspended in 1 mL/10 g leaf
tissue of 10 mM Sodium Phosphate buffer, pH 7.2, filter sterilized. Resuspended pellets
were clarified at 7,000 x G for 7 minutes and supernatant collected and analyzed for
protein concentration using BCA (Pierce). Clarified virus extracts were then diluted to 1
mg/mL using 10 mM Sodium Phosphate buffer and diluted 1:1 with 0.9% sterile saline
for injection to a final concentration of 0.5 mg/mL.
Virus Assembly Tests

Assessment of TMV-(PA1-PA16) viral capsid assembly was performed since it is
probable that the addition of heterologous amino acids onto the TMV coat protein could
disrupt normal protein folding or capsid assembly around the RNA genome. To
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investigate this, recombinant viral RNA inoculated leaves and non-inoculated upper
leaves were removed separately, pulverized using a mortar and pestle in ~2-3 volumes
phosphate buffer and filtered through 2-layers of cheesecloth. Nicotiana tabacum Xanthi
nc (i.e. “Glurk”) is resistant to TMV infection and forms local necrotic lesions (LNL) that
block viral movement and systemic infection. Leaves from young Glurk plants were
dusted with Celite® and 200 μL of green extract was pipetted and gently rubbed evenly
over the surface of the leaves and incubated in the growth chambers as described
previously. LNL developed after ~5 days if assembled TMV particles were present in the
green juice extract. This is due to the fact that free, unassembled viral RNA would have
been degraded by nucleases if it had not been protected by assembly of the coat protein
capsid. Further confirmation of viral assembly is the presence of TMV in the upper, noninoculated leaves. This indicates that the virus moved systemically through the phloem
tissue which is only possible if the coat protein assembles around the TMV RNA
genome. Uncoated RNA cannot move through the plant vasculature.
TMV-PA4 Construct Redesign

Based on the observation by others that LNL induced in susceptible N.
benthamiana can be mitigated through the addition of negatively charged amino acid
residues (Aspartic Acid-“D” or Glutamic Acid-“E”) between the coat protein and the
epitope97, and that linker sequences may allow Tobamovirus capsids to accommodate
larger sized amino acid insertions98, TMV-PA4 constructs were re-designed to
incorporate these characteristics in hopes that N. benthamiana would be susceptible to
infection with TMV carrying the PA4 peptide. Previously, TMV Coat Protein U1 genes
were PCR amplified to introduce an AvrII restriction site at the N-terminus and added
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linker sequences, (GGGGS x 3) or (EAAAK x 3), at the C-terminus followed by an
EcoRV site. The primers used for the coat protein linker modifications are in Table 4.

Primer Name

Sequence (5’→ 3’)

Tminitial/Tmfinal
(°C)

Concentration
used in PCR
(μM)

% GC

TMV CP
Forward AvrII

CTA CTC CAC CCC
TAG GAT GTC TTA
CAG

52/60

0.5

52

TMV CP
Reverse
EcoRV

CCA CTG ATA TCA
GTT GCA GGG CCA G

51/63

0.5

56

TMV CP
Glycine
Linker
Reverse
EcoRV

CCA CTG ATA TCA
CTA CCA CCA CCA
CCA CTA CCA CCA
CCA CCA CTA CCA
CCA CCA CCA GTT
GCA GGG CCA G

49/80

0.05

59

TMV CP
Glycine
Linker
Reverse
EcoRV
Finishing

CCA CTG ATA TCA
CTA CCA CCA CC

58

0.5

52

TMV CP
Helical Linker
Reverse
EcoRV

CCA CTG ATA TCC
TTA GCA GCA GCT
TCC TTA GCA GCA
GCT TCC TTA GCA
GCA GCT TCA GTT
GCA GGG CCA G

51/77

0.05

54

TMV CP
Helical Linker
Reverse
EcoRV
Finishing

CCA CTG ATA TCC
TTA GCA GCA G

55

0.5

50

Table 4: PCR primers for TMV coat protein glycine (GGGGS x 3) or helical (EAAAK x 3) linker
additions

PCR reactions were performed in 25 μL volumes with 10 ng of TMV U1 coat
protein template plasmid and reverse primers (TMV CP Reverse EcoRV, TMV CP
Glycine Linker Reverse EcoRV or TMV CP Helical Linker Reverse EcoRV) paired with
the TMV CP Forward AvrII primer using Taq DNA polymerase (NEB). Taq buffer,
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dNTPs and Taq polymerase were used at concentrations according to the manufacturer’s
instructions. Ten cycles of PCR were completed at annealing temperatures 5°C below
Tminitial of the primer with the lowest Tminitial between the pair. For reactions including
linker addition primers, at cycle 10, the PCR reaction was stopped and Reverse Finishing
primers were added to the respective reactions. Twenty more rounds of PCR were
completed with annealing temperatures as described above. The TMV CP GL/HL
Reverse EcoRV Finishing primers were designed to complete the 20 rounds of PCR at an
annealing temperature more compatible with the PCR format since the long linker
additions on the first round reverse primers would necessitate very high annealing
temperatures at the later stages of PCR. Reactions were cleaned using DNA Clean &
Concentrate-5 spin columns (Zymo) and cloned into the PCR® 2.1 TOPO® TA cloning
vectors (Life Technologies) (Figure 14 Supplemental), (Figure 15 Supplemental) and (Figure 16
Supplemental). Topo vector containing TMV coat proteins with/without linker additions

and AvrII/EcoRV flanking restrictions sites were sequenced for verification (Laragen)
using the M13 Forward (GTA AAA CGA CGG CCA GT) and M13 Reverse (CAG GAA
ACA GCT ATG AC) primers.
Insertion of aspartic acid residues in between the PA4 epitope sequence and the
TMV coat protein (with/without glycine or helical linker sequences) was accomplished
through PCR. Primers were designed to amplify the PA4 sequence and add an EcoRV
site to the C-terminal end of the gene with or without added codons for aspartic acid
(Table 5). It should be noted that the EcoRV restriction site GATATC codes for aspartic
acid and isoleucine thus all peptide additions using this site contain these extra amino
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acids in between the coat protein and the peptide fusion. A reverse primer was used to
include the NotI cloning site at the N-terminal end of the PA4 sequence (Table 5).
Primer
Name
PA4 EcoRV
Forward

DD-PA4
EcoRV
Forward
TMV Coat
Protein RTPCR Reverse

Sequence (5’→ 3’)
TTA ATT GAT
ATC CAA TTG
CCT GAA TTG
AAA CA
TTA ATT GAT
ATC GAT GAT
CAA TTG CCT
GAA TTG AAA
CA

Tminitial/Tmfinal
(°C)

Concentration used
in PCR (μM)

% GC

49/56

0.2 μM

28/35

49/59

0.2 μM

29

55

0.2 μM

53

CGC TTT ATT
ACG TGC CTG C

Table 5: PCR primers for amplification and modification of PA4 peptide sequence for insertion onto TMV
coat protein C-terminus with or without linkers

Fifty μL volume PCR reactions were performed with each forward primer paired with the
TMV Coat Protein RT-PCR Reverse primer. Ten rounds of PCR were completed using
annealing temperatures 4°C below the Tminitial for the forward primers and the following
20 rounds were completed at annealing temperatures 4°C below the Tm for the TMV
Coat Protein RT-PCR Reverse primer. The DN15-TCS-TMV-CP-PA4 vector was used
as a template at 3.8 ng with OneTaq DNA polymerase (NEB) according to the
manufacturer’s instructions. PCR products were purified using the DNA Clean &
Concentrate-5 kit (Zymo) and digested with EcoRV-HF/NotI-HF (NEB) according to the
manufacturer’s instructions. PA4 peptide sequences were then cloned into the TopoTMV CP, Topo-TMV CP-Glycine Linker or Topo-TMV CP-Helical Linker vectors.
Plasmids were screened for proper insert size using colony PCR with M13 Forward and
M13 Reverse primers. TMV coat proteins genes with or without linkers and the modified
PA4 inserts were digested with AvrII and NotI-HF (NEB) and cloned into the DN15-TCS
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vector. DN15-TCS vectors containing modified coat proteins were sequenced as before
with the TMV CP RT-PCR Forward and TMV CP RT-PCR Reverse primers (Laragen).
Recombinant TMV constructs expressing the modified PA4 inserts were transcribed as
described previously for inoculation and expression in N. benthamiana.
Reverse Transcription-PCR and Sequencing

In order to determine if the genetic sequence of the TMV-CP with PA peptide
fusions was maintained over the course of the virus infection, viral RNA was purified,
reverse transcribed into cDNA, amplified using PCR and sequenced. Five to ten mg of
viral extracts were precipitated in a final concentration of 4% PEG 8,000 and 0.68M
NaCl and pelleted in a refrigerated microcentrifuge as described previously. Viral pellets
were resuspended in a solution of 0.1M NaCl, 10 mM Tris-Cl pH 7.6, and 1 mM EDTA
at approximately 20 mg/mL. Two volumes of phenol: chloroform (1:1, pH 8.0) was
added to the resuspended viral extracts and briefly vortexed. Samples were centrifuged at
16,000 x G for 30 minutes at 4°C. Pure RNA was extracted from the aqueous layer using
RNA Clean and Concentrator™ spin columns (Zymo Research). Samples were DNAse
treated on the columns using RQ1 RNAse-free DNAse (Promega) according the
manufacturer’s instructions. RNA samples were checked for purity and concentration
using a Tecan Nanoquant plate reader. Reverse transcription reactions were performed
using M-MLV Reverse Transcriptase H-Point Mutant (Promega) with 1 μg of extracted
RNA and 125 ng of random hexamers (Invitrogen, Product Number 58875) according to
the manufacturer’s instructions. PCR reactions were performed in 50μL reaction volumes
with 1 μL of TMV cDNA from reverse transcription as template, 200 μM dNTPs,
OneTaq DNA polymerase (NEB), 1x OneTaq Buffer, and 1 μM each of TMV Coat RT50

PCR Forward, 5’ GAT CTT ACA GTA TCA CTA CTC CAT CTC 3’, and TMV Coat
RT-PCR Reverse, 5’CGC TTT ATT ACG TGC CTG C3’. Reactions were thermocycled
through 30 cycles of PCR with 94°C melting, 49°C annealing and 68°C extension
temperatures. Reactions were run on 1% agarose in TAE (40 mM Tris-acetate, 1 mM
EDTA) at 100V for 1.5 hours. DNA bands of expected size were excised, gel purified
(Zymo Research) and Sanger sequenced using the TMV Coat RT-PCR Forward and
Reverse primers (Laragen).
Analysis of TMV-PA Antigens for Reactivity against PA Specific Antibodies
SDS-PAGE, ELISA and Western Blots
Purified TMV viruses were prepared 1:1 in Laemmli Blue with βmercaptoethanol, boiled and run at 200V for 35 minutes on 4-20% Mini-Protean TGX
gels (BioRad) in 1x Tris/Glycine/SDS buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS,
pH 8.3) and stained with BioSafe Coomassie G-250 stain (BioRad) according to
manufacturer’s direction. For westerns, gels were transferred onto 0.2 um nitrocellulose
membranes (7 cm x 8.5 cm) in Tris-Glycine buffer (25 mM Tris, 192 mM Glycine, 20%
Methanol, pH 8.3) for 1 hour at 100V. Membranes were blocked with 2.5% non-fat milk
in TBS (20 mM Tris, 150 mM NaCl, pH 7.6) for 1 hour at room temperature. Primary
antibody (Goat anti-PA polyclonal, List Biologics Lot # 7712A2 or Rabbit anti-TMV
polyclonal, Agdia Lot # 00830) diluted in 10 mL blocking buffer at 1:1000 (anti-PA) or
1:200 (anti-TMV) was incubated with the membrane overnight at 4°C gently shaking.
Membranes were washed in TBS and TBS-tween (0.1%) for a total of 20 minutes at room
temperature. Secondary antibody (Goat anti-Rabbit-Horse Radish Peroxidase (HRP),
BioRad Lot #L9701107 or Rabbit anti-Goat HRP, Life Technologies Lot #27-11051

040113) diluted in 10 mL blocking buffer at 1:3,000 (Goat anti-Rabbit) or 1:2,000
(Rabbit anti-Goat) was incubated with the membrane gently rocking for 1 hour at room
temperature. Washes were performed as previously stated and 15 mL/membrane of Opti4CN (BioRad) reagent was added for 5 minutes for detection. Membranes were then
rinsed with water and photographed. For Indirect ELISA analysis of TMV-wild type (wt),
TMV-PA6 and TMV-PA12, Costar 96-well flat bottom medium bind EIA/RIA plates
(Corning) were coated with 50 μL/well of 20 μg/mL PA or TMV virus in 100mM
Bicarbonate/Carbonate (0.03 M Na2CO3/0.07 M NaHCO3), pH 9.6 overnight at 4°C.
Plates were then washed 3 times with 200μL/well Dulbecco’s PBS (136.9 mM NaCl, 2.7
mM KCl, 8.9 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4). Five percent non-fat milk diluted
in PBS was used to block wells for 2 hours at room temperature. Primary antibody (Goat
anti-PA polyclonal, List Biologics) diluted in blocking buffer was added (100 μL/well)
and incubated overnight at 4°C. Plates were washed 4 times with PBS (200 μL/well).
Secondary antibody (Rabbit anti-Goat, Life Technologies) diluted to 1:2,000 in blocking
buffer was added (100μL/well) and incubated at room temperature for 2 hours. Secondary
antibody was removed and plates were washed 4 times as before. OPD (Sigma, Lot#
NG15258421) detection reagent was prepared according to manufacturer’s instruction
and added (100 μL/well). Plates were developed for 30 minutes then read at Abs. 450 nm.
PA was purchased from List Biologicals, product #171B.
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Immunization of Mice with TMV-PA Antigens and Screening for PA Specific
Antibodies in Serum
Vaccination and Serum Collection

The vaccination protocol was designed based on a thorough review and
comparison of the literature of TMV virus nanoparticle vaccines. All animal experiments
were performed in accordance with Institutional Animal Care and Use Committee
(IACUC) standards under approved protocols through the Kenneth Bradley Lab at the
University of California, Los Angeles. Seven week old female C57BL/6J mice (Jackson
Laboratories) received three intraperitoneal (IP) injections two weeks apart with 50 μg
TMV, TMV-PA6, TMV-PA12 or a 1:1 mixture of TMV-PA6 and TMV-PA12 (Figure 3).
Serum was harvested from anesthetized mice in the bleed groups by taking blood samples
through the retro-orbital sinus before each vaccination at days 0, 14, 28 and 35. After
final vaccine injection, mice in the serum harvest groups were euthanized and their serum
was harvested through a cardiac puncture. All blood samples were allowed to clot for at
least 30 minutes and then centrifuged for 10 minutes at 1,500 x G. Serum was removed
from the pellet and frozen at -20°C until further analyses were performed.
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Figure 3: C57BL/6J mouse vaccination schedule with TMV wild-type, TMV-PA6, TMV-PA12 or a 1:1
combination of TMV-PA6 and TMV-PA12
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Serum Antibody Titer Analysis

This experiment was used to determine whether TMV-PA vaccinations induced
cross-reactive antibodies against native PA83 and the titers they reached by the time mice
were challenged with B. anthracis spores. Clear 96-well half area polystyrene plates
(Corning) were coated with 25 μL of either PA or TMV antigen at 20 μg/mL in 100 mM
Bicarbonate/Carbonate buffer overnight at 4°C as before. Plates were washed twice with
PBS and blocked with 5% non-fat milk dissolved in PBS for 2 hours at room
temperature. Fifty μL volumes of serum samples (beginning at 1:100 and serially diluted
3-fold to 1:656,100) diluted in blocking buffer were added to wells coated with PA, TMV
antigen, or blocking buffer and incubated overnight at 4°C. Wells were washed 4 times
with PBS and 50 μL of Goat anti-mouse IgG HRP conjugate (BioRad) diluted at 1:3,000
in blocking buffer was applied to each well and incubated at room temperature for 2
hours. Following 4 final washes with PBS, 50 μL of OPD substrate, prepared according
to the manufacturer’s directions, was added to each well and incubated at room
temperature for 30 minutes. Wells were read at Abs. 450 nm. End-point titers were
determined as the last dilution at which the Abs. 450 nm was above a cutoff. Cutoff
values, for each dilution, were determined as the upper prediction limit at a 95%
confidence level using the student t-distribution from n=16 pre-immune serum samples99.
Spore Challenge of Immunized Mice and Testing of Serum for LT Neutralizing
Antibodies in a Cell Survival Assay
Total Neutralizing Antibody Activity Assay

This experiment was performed in order to test if antibodies induced by TMV-PA
vaccinations neutralized anthrax LT. RAW 264.7 macrophages were grown in a 25 cm2
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petri dish at 37°C, 5% CO2 in Dulbecco’s Modified Eagle Medium with 10% Fetal
Bovine Serum and 1% penicillin-streptomycin (DMEM+10/PS). Once cells reached 50%
confluence, media was removed and cells were washed once with PBS then incubated at
room temperature with 7 mL PBS/trypsin for 3 minutes. Three mL’s DMEM+10/PS was
added and cells were washed off plate and placed in a 15 mL centrifuge tube and pelleted
at 1,500 x G for 2 minutes. Supernatant was removed and cells were resuspended in 10
mL DMEM+10/PS, counted and plated at 5,000 cells/well in ½ area polystyrene 96-well
tissue culture plates (Corning) and incubated 18 hours overnight at 37°C, 5% CO2. The
next morning, pooled serum samples by vaccine group were prepared with or without
anthrax LT in DMEM+10/PS and incubated 1 hour at room temperature. PA toxin
concentrations were varied from 62.5-250 ng/mL while LF toxin was used at a constant
500 ng/mL. Positive control serum was obtained from a mouse that survived challenge
from B. anthracis Sterne strain spores from a previous study and was found to have
significant levels of neutralizing anti-PA antibodies. Following incubation, 50 μL/well
sample volumes were added to cells and incubated 24 hours at 37°C/5% CO2. Plates were
then emptied and 50 μL/well of DMEM+10/PS with MTT (3-(4,5-dimethylthiazolyl-2(2,5-diphenyltetrazolium bromide) was added and incubated for 30 minutes at 37°C/5%
CO2. Following incubation, plates were emptied and 50 μL/well of DMSO was added
and plates were shaken for 10 seconds and read at Abs. 570 nm. Data was analyzed using
Microsoft Excel. Cells treated with media/serum/toxin were normalized against cells
incubated with their respective serum/media without toxin.
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Animal Challenge with B. anthracis Spores

One week following the final vaccination, mice in the challenge groups were
injected in the peritoneal cavity with 100μL of 2.5 x 108 cfu/mL Sterne strain Bacillus
anthracis spores such that each mouse received 2.5 x 107 cfu. Spores were a gift from Dr.
Chris Cote, USAMRIID and stored at 4°C until use. Spores were prepared in sterile water
for injection, heat shocked at 65°C for 30 minutes to kill any potentially germinated
spores or vegetative bacilli, then plated on LB plates at serial dilutions to confirm cfu/mL
counts. Challenged mice were observed twice a day and their health was graded on a
scale from 0-3 where 0 represented healthy and 3 represented moribund (no motility,
squinted eyes, ruffled fur). Animals were euthanized when they reached a level 2 health
grade (symptoms included low motility, weakness, possibly ruffled fur and squinted
eyes). Kaplan-Meier survival analysis was performed using GraphPad Prism software
and statistical significance was calculated using the Log-Rank test.
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Chapter 4-Results
Expression and Assembly of TMV-PA Vaccine Constructs

TMV displaying PA peptide epitopes were expressed in N. benthamiana through
inoculation with T7 transcribed RNA from DN15-TCS plasmids containing recombinant
coat protein-PA peptide clones. Plant leaf tissue was tested for the presence of assembled
virus using the “Glurk” test and virus purified as described in chapter 3. In total, 12 of 16
constructs tested positive for LNL on Glurk indicating that they assembled with
recombinant coat proteins (Table 6). However, RT-PCR and sequencing analysis of the
RNA genomes revealed that TMV-PA3 and TMV-PA13 had experienced genetic drift
causing either deletion or mutation of the epitope sequence. Eight of the twelve viruses
that tested positive for assembly also had conserved epitope sequences on a genetic level.
TMV-PA4 induced LNL in N. benthamiana and suitable amounts of virus were not able
to be obtained for testing (Figure 4A and B). TMV-PA9 tested positive for assembly and
systemic movement from lower inoculated leaves to upper non-inoculated leaves but
extraction of virus failed also resulting in the inability to determine the fidelity of its
genetic sequence through RT-PCR and sequencing. TMV-PA5, TMV-PA13, TMVPA14, TMV-PA15 and TMV-PA16 did not show any systemic signs of infection in N.
benthamiana and did not show presence of LNL on Glurk.
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Construct

Insert Size
(Amino
Acids)

Coat Protein
Expected
pI/kD

Virus
Assembly
“Glurk” Test

Purification and Yield

RTPCR/Sequencing

TMV-wt
coat

n/a

5.09/17.6

Positive

4 mg virus/g leaf tissue

Conserved

TMV- no
coat

n/a

n/a

Negative

n/a

n/a

TMV-PA1

12

5.47/19.0

Positive

Undetermined

Epitope Conserved

TMV-PA2

14

7.85/19.3

Positive

Undetermined

Epitope Conserved

TMV-PA3

20

5.49/20.0

Positive

Undetermined

Epitope Deletion

Induced Necrotic
Lesions

n/a

TMV-PA4

20

9.20/19.9

Not Determined

TMV-PA5

14

6.27/19.3

Negative

n/a

n/a
Epitope Conserved

TMV-PA6

16

5.17/19.5

Positive

0.7 mg virus/g leaf
tissue

TMV-PA7

14

6.28/19.2

Positive

Undetermined

Epitope Conserved

TMV-PA8

18

5.09/19.3

Positive

Undetermined

Epitope Conserved

TMV-PA9

10

5.42/18.8

Positive

Failed

Not Tested

TMV-PA10

14

5.42/19.2

Positive

Undetermined

Epitope Conserved
Epitope Conserved

TMV-PA11

12

5.42/19.0

Positive

0.3 mg virus/g leaf
tissue

TMV-PA12

10

5.45/18.8

Positive

0.5 mg virus/g leaf
tissue

Epitope Conserved

TMV-PA13

10

5.46/18.8

Positive

Undetermined/Low

Frame Shift

TMV-PA14

18

5.45/19.8

Negative

n/a

n/a

TMV-PA15

16

5.10/19.3

Negative

n/a

n/a

TMV-PA16

15

7.86/19.4

Negative

n/a

n/a

Table 6: Expression characteristics of recombinant TMV with modified coat proteins fused to PA peptides
at the C-terminus

The wild-type TMV U1 coat protein has a molecular weight of 17.6 kD, an
isoelectric point (pI) of 5.09 and a net charge of -2 at neutral pH. TMV-PA constructs
that did not assemble or systemically infect N. benthamiana had an average insert size of
16.14 amino acids, PA peptide inserts with an average pI of 8.92 and an average net
charge of +2 (Table 7). In contrast, TMV-PA constructs that successfully assembled and
established a systemic infection had PA peptide inserts that averaged 13.33 amino acids
long, PA peptide inserts with an average pI of 8.44 and an average net charge of +1 (Table
7). In addition, constructs that established successful systemic infections had PA peptide

inserts composed, on average, of 40.1% polar amino acids while those that did not
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assemble or systemically infect plants were only composed of 31.7% of polar amino

Median Net Charge

Mean Net Charge

% Composition of Positively
Charged amino acids (Mean)
% Composition of Negatively
Charged amino acids (Mean)
% Composition of Polar amino acids
(Mean)
% Composition of Non-Polar amino
acids (Mean)

Median pI

Mean pI

Median molecular weight (kD) of
Insert

Mean molecular weight (kD) of
Insert

Median Insert Size (amino acids)

Mean Insert Size (amino acids)

Sample Size

acids (Table 7).

Non Systemic/Non
7 16.14 16 1.88
1.8 8.92 8.5 20.1 8.7 31.7 39.6 2 1
Assembled
9 13.33 14 1.50 1.56 8.44 8.59 16.6 7.7 40.2 35.5 1 1
Systemic/Assembled
Wild-Type TMV Coat
1 159 n/a 17.6
n/a 5.09 n/a 8.2 9.4 36.5 45.9 -2 n/a
Protein U1
Table 7: Comparison of PA peptide properties between recombinant coat protein-PA peptide fusion
constructs that successfully assembled and established a systemic virus infection and constructs that did not
assemble or establish a systemic virus infection

TMV-PA extracts that yielded enough protein for SDS-PAGE analysis revealed
coat protein monomers of various sizes. SDS-PAGE analysis under reducing conditions
showed that TMV-WT coat protein migrated to its expected 17.6 kD (Figure 5A, Lane 3)
while TMV-PA6, TMV-PA11, TMV-PA12, and TMV-PA1 contained multiple bands
running between 17.6 kD and ~20 kD (Figure 5A, Lanes 4, 6, 7 and 9 respectively). Western
blot analysis with anti-TMV coat protein antibody confirmed the identity of the bands
between 17.6 kD and ~20 kD for each of these constructs (Figure 5B). The higher
molecular weight bands in these constructs compares well to the expected size of their
modified coat protein monomers (Table 6). TMV-PA7 was the only construct that
appeared as a single band at its expected molecular weight of 19.2 kD (Figure 5A, Lane 10)
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and was confirmed in western (Figure 5B, Lane 10). TMV-PA8 was not in high enough
protein concentrations for analysis (Figure 5A, Lane 5). Protein yields from select virus
extracts ranged between 0.32 mg/g (TMV-PA11) to 4 mg/g fresh leaf tissue (TMV-wt
coat protein) (Table 6).
Expression and Assembly of Redesigned TMV-PA4 Vaccine Constructs

TMV-PA4 constructs elicited LNL in N. benthamiana plants and could not be
expressed in high enough quantities to obtain sufficient amounts of virus for testing.
Redesigned constructs were made that introduced negatively charged aspartic acid (D)
residues in between the PA4 peptide and the TMV coat protein, introduction of linkers
between the PA4 peptide and TMV coat protein or both (Figure 4C). The addition of either
a flexible (GGGGS x 3) or helical (EAAAK x 3) linker sequence between the coat
protein and PA4 peptide did not change the isoelectric point or net charge of the fusion
protein (Figure 4C). However, the addition of two aspartic acid (DD) residues in between
the peptide and the coat protein, with or without a linker, lowered the isoelectric point/net
charge of the fusion protein from ~8.8/+2 down to ~6.3/0 (Figure 4C). However, all
redesigned constructs elicited LNL in susceptible N. benthamiana (Figure 4D) and N.
tabacum Xanthi (data not shown).
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A

B

C

D
Coat Protein C’
Term – PA4

Coat Protein C’
Term – Glycine
Linker – PA4

Coat Protein C’
Term – Helical
Linker– PA4

No
“DD”

8.81/+2

8.81/+2

8.73/+2

Plus
“DD”

6.27/0

6.31/0

6.36/0

TMV-CP-PA4

TMV-CP-DDPA4

TMV-CP-GLPA4

TMV-CP-GLDD-PA4

TMV-CP-HLPA4

TMV-CP-HLDD-PA4

Figure 4: Induction of LNL by TMV-PA4 and its redesigned derivatives. N. benthamiana five days post
inoculation with T7 transcribed TMV-PA4 RNA (A) and two weeks (B). Isoelectric point and net charge at
neutral pH of TMV-PA4 derivatives with or without added DD amino acids and linkers (GGGGS x 3) or
(EAAAK x 3) (C). N. benthamiana five days post inoculation with T7 transcribed TMV-(Linker)(DD)-PA4
derivative RNA (D).

Cross-Reactivity of TMV-PA Constructs with Antibodies Raised against Native PA

TMV displaying PA peptides showed cross-reactivity with goat antibodies raised
against native PA. In western blot, the largest coat protein band in TMV-PA6 showed a
strong signal when probed with anti-PA antibodies (Figure 5C, Lane 4). TMV-PA1, TMVPA7, TMV-PA8 (concentration too low), TMV-PA11 and TMV-PA12 did not show a
signal in western blot against anti-PA antibodies. TMV-PA6 showed a strong signal in
ELISA (Figure 5D) against anti-PA antibodies while TMV-PA1 (data not shown) and
TMV-PA12 showed modest reactivity (Figure 5D). TMV-PA7 and TMV-PA11 did not
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show any reactivity in ELISA above the background (data not shown). Other
recombinant viruses that were positive for assembly, such as TMV-PA2, TMV-PA9,
TMV-PA10 and retesting of TMV-PA8 were not performed due to low viral yields in
plant extracts.
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Figure 5: SDS-PAGE (A) and western blot analysis of purified TMV-PA constructs with anti-TMV
primary antibody (B) and anti-PA primary antibody (C). Lane 1 – Standards, 2 – PA83, 3 – TMV-wt, 4 –
TMV-PA6, 5 – TMV-PA8, 6 – TMV-PA11, 7 – TMV-PA12, 8 – TMV-wt, 9 – TMV-PA1, 10 – TMVPA7. Indirect ELISA analysis of purified TMV-PA constructs against anti-PA antibody (D).

Due to the observation that multiple coat protein bands of various sizes were
present after viral extraction in some of the purified virus extracts, experiments were
performed to test the stability of the PA peptide epitope on TMV. TMV-PA6 was chosen
for testing due to its strong reactivity to anti-PA antibodies making it easy to detect loss
of signal. Fresh TMV-PA6 extracts were incubated at 37°C, room temperature, 4°C and 20°C for two weeks and tested in ELISA against anti-PA antibodies. Only purified TMV63

PA6 frozen at -20°C retained its reactivity against anti-PA antibodies while TMV-PA6
viruses incubated at temperatures from 4°C and higher completely lost reactivity (Figure
6B). In addition, SDS-PAGE analysis confirmed that TMV-PA6 extracts degraded to

wild-type TMV coat protein size after 3 months at 4°C (Figure 6A). TMV-PA12 exhibited
similar behavior in SDS-PAGE (data not shown).

A

B

1.6
1.4

TMV-PA6
(3 months at 4°C)

TMV-PA6 (Fresh)

Abs. 450 nm

1.2

Coating Antigen
PA

1
0.8

TMV-PA6 (-20 C)

0.6

TMV-PA6 (4 C)
TMV-PA6 (RT)

0.4

TMV-PA6 (37 C)
0.2
0
30

15

7.5

3.75

1.875

-0.2

Goat Anti-PA Antibody (μg/mL)

Figure 6: Analysis of the stability of TMV-PA6 using SDS-PAGE (A) and ELISA (B)

Vaccination and Analysis of Antibody Titers

Due to the prior report that PA6 and PA12 specific antibodies were protective in
vivo78, we chose to evaluate TMV-PA6, TMV-PA12 and TMV-PA6/TMV-PA12
combination vaccines compared to TMV-WT through IP injections of C57BL/6J mice on
days 1, 15 and 29 with 50 µg of the vaccine preparation without adjuvant (Figure 3).
ELISA analysis of pre-immune serum from serum harvested vaccine groups, extracted on
day 0, showed no reactivity to immobilized PA83 or TMV antigen (Figure 7 and Figure 8).
All mice vaccinated with TMV-PA6, TMV-PA12, or TMV-PA6/TMV-PA12 showed
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cross-reactive IgG antibodies to PA83 by day 29 and reached their peak by day 35 (Figure
7). TMV-PA6 vaccinated mice developed PA specific antibodies to titers between

1:8,100 and 1: 24,300 that were detectable by day 14 while TMV-PA12 vaccinated mice
only developed PA specific antibody titers between 1:900 and 1:8,100 that were only
detectable by day 29 (Figure 7). And mice vaccinated with a combination of TMV-PA6
and TMV-PA12 achieved maximal titers between 1:2,700 and 1: 218,700 (Figure 7). Mice
vaccinated with TMV-WT showed no reactivity to PA83 by day 35 (Figure 7). IgG
antibodies against the TMV antigen showed robust reactivity beginning at day 14 and
reached saturation points by day 35 in all treatment groups even at dilutions as high as
1:656,100 (Figure 8).
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Figure 7: End-point serum titers of PA specific antibodies in individual mice vaccinated with TMV or
TMV-PA vaccine constructs in the “serum harvested” vaccine groups detected using ELISA
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Figure 8: End-point serum titers of TMV specific antibodies in individual mice vaccinated with TMV or
TMV-PA vaccine constructs in the “serum harvested” vaccine groups detected using ELISA.

In Vivo Efficacy of TMV-PA Vaccines against Anthrax Spore Challenge
Mice in the spore challenge vaccine groups were injected on day 36 with 2.5 x 107
cfu/mouse B. anthracis Sterne strain spores. Separate experiments determined that this
dose would be required to kill at least 90% of mice (data not shown). All mice in the
TMV and TMV-PA6/TMV-PA12 treatment groups succumbed to infection 73-hours post
spore injection (Figure 9). Four of five mice died 73-hours post injection in the TMV-PA6
treatment group, while three of five mice died at 73-hours in the TMV-PA12 treatment
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group. Two mice survived the spore challenge with one each in the TMV-PA6 and TMVPA12 treatment groups.

Figure 9: Kaplan-Meier survival analysis of C57BL/6J mice vaccinated with TMV-wt or TMV-PA vaccine
constructs after challenge with Sterne strain B. anthracis spores (2.5 x 107 cfu/mouse). P-values were
calculated using the Log-Rank test.

In Vitro Lethal Toxin Neutralization Analysis with Serum from Vaccinated Mice

Antibodies induced against the PA6 or PA12 epitope using TMV-PA6 and TMVPA12 vaccine candidates were not found to have LT neutralization capacity in cellular
assays. Pooled serum from TMV-PA6, TMV-PA12 and TMV-PA6/PA12 vaccinated
mice, diluted at 1:10 in cell culture media, prevented the death of 50%, 68% and 82% of
macrophages treated with 62.5 ng/mL PA and 500 ng/mL LF normalized using respective
serum treated cells lacking LT. However, serum from TMV-WT vaccinated mice
protected similarly well by preventing the death of 77% of macrophages treated with 62.5
ng/mL PA and 500 ng/mL LF. Increased PA concentrations revealed a similar trend
(Figure 10).
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Figure 10: Total neutralizing antibody assay with RAW 264.7 macrophages treated with LT and serum
from TMV-wt or TMV-PA vaccinated mice from the “serum harvested” vaccine groups. Data is
representative of two separate experiments.
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Chapter 5-Discussion
Expression Characteristics

Tobacco Mosaic Virus supports expression of the majority of B. anthracis
peptides selected in this study. Nine of 16 constructs assembled correctly and maintained
the proper genetic sequence of the inserted peptides while the remaining 7 either did not
show signs of assembly and systemic propagation in N. benthamiana host plants, elicited
LNL, or displayed premature truncation of the inserted PA peptide. Coat protein-PA
peptide constructs that assembled correctly and maintained the correct genetic sequence
throughout viral infection showed a general trend of allowing shorter PA peptide inserts
(13.33 amino acids in length on average), with lower isoelectric points (8.44 mean pI), a
higher percentage of polar amino acids (40.2 %) and a lower percentage of positively
charged amino acids (16.6%) compared to coat proteins with PA peptide inserts that did
not assemble, elicited LNL, or experienced mutations in the PA peptide sequence (Table
7). On average, the properties that were associated with successful presentation of B.

anthracis peptides on the surface of TMV coat protein showed a tendency to be more
reminiscent of the properties of the wild-type U1 coat protein. This observation is
consistent with the fact that TMV has co-evolved with plants from the Solanaceae family
for many millennia and has optimized characteristics for successful infection and
transmission. Altering the surface properties of the coat protein is likely to cause the
resulting virus particles to be less fit or non-functional in expression.
Some peptide sequences elicit plant specific responses that block successful TMV
expression and systemic infection. The TMV-PA4 construct elicited LNL that prohibited
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systemic infection. There are published reports of other TMV constructs that elicit this
response97,100. One of these reports identified a sequence fused to TMV coat protein that
consisted of 83.3% non-polar amino acids and was predicted to be a transmembrane
domain101. Another construct was reported in which it was shown that the peptide
isoelectric point (11.72) and net charge at neutral pH (+4) were responsible for inducing
LNL97. It was shown that this problematic coat protein peptide fusion could be “rescued”
through the addition of acidic amino acids, such as aspartic acid or glutamic acid, which
lowered the isoelectric point and net charge of the coat protein-peptide fusion. The PA4
peptide consists of 20% non-polar amino acids, 45% polar amino acids, an isoelectric
point of 11.2, and a net charge of +5. These properties were very similar to those
described in the previous report97 and led me to the hypothesis that this peptide could
possibly be rescued through the addition of negatively charged, acidic residues such as
aspartic acid. Additionally, one report describes incorporation of larger sized constructs
of up to 133 amino acids by using a flexible or helical linker sequence to space the
heterologous sequence away from the assembled coat protein capsid98. Attempts made to
rescue failed TMV-PA4 expression by employing these two strategies by themselves or
in combination did not work (Figure 4C, D). Indeed, LNL were still elicited in each
modified TMV-PA4 construct, with or without linkers and with or without added acidic
amino acids. This work shows that other factors may be important for inducing LNL
other than peptide isoelectric point and net charge of the coat protein fusion. The PA4
epitope contains the furin cleavage site RKKR that is required for PA20 to be released
from the PA83 molecule once it binds to the cell surface. Furin sequences are not known
to be cleaved in plants and PA83 expressed as a recombinant protein in plants, without
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induction of LNL, was found to be structurally intact and not lacking the PA20
component45,102. This indicates that it is not the furin site per se that is inducing LNL but
perhaps the way it is presented as a repetitive array on the TMV surface that is activating
the necrotic response. More investigation is needed in the field of TMV-peptide fusion
characteristics and their induction of LNL to define what methods might be used to
overcome this limitation.
Purification of TMV-PA constructs revealed the expected size increase of coat
protein monomers with PA peptide additions. It was also observed that specific virus
constructs, TMV-PA6 and TMV-PA12, showed multiple coat protein bands present in
viral extracts that were in between the expected size and wild-type coat protein size
(Figure 5A, Lanes 4 and 7). Initially it was thought that this was caused by genetic revertants
that had lost the PA peptide sequence, or a portion of it, during infection due to the
absence of selective pressure. An alternative explanation is that the epitope sequence is
undergoing proteolytic cleavage at specific locations either in planta or after extraction.
Numerous infections through inoculation with T7 transcribed RNA from DNA plasmid
stocks followed by analysis of the purified TMV-PA6 and TMV-PA12 viruses showed
the same coat protein migration patterns on SDS-PAGE. Also, observations that the
TMV-PA6 molecule gradually loses reactivity with anti-PA antibody over time and that
these viruses eventually completely degrade to wild-type coat protein size on SDS-PAGE
suggests that the epitope sequences are undergoing proteolytic cleavage during and
following virus extraction, although more experiments would need to be performed to
rule out the possibility that the epitope may also be undergoing some levels of
degradation in planta.
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Peptide stability on the surface of TMV coat protein appears to be governed by a
number of factors. Some constructs, TMV-PA7 and TMV-PA11, do not contain
degradation products after purification (Figure 5A, Lanes 6 and 10). In addition, other reports
have found that peptides which were unstable on the C-terminus showed stability on the
N-terminus and vice versa93. Finally, it has also been reported that the purification
conditions, such as temperature, are also an important factor for maintaining heterologous
peptide integrity on the coat protein surface93. These observations indicate that the
specific amino acid composition of a particular peptide and its context with surrounding
amino acids from the coat protein are important factors for stability. This suggests that
any peptide can be stabilized through the insertion of specific amino acids in between the
peptide and the TMV coat protein or through changing the position at which the peptide
is displayed on the coat protein. Other strategies may be to alter processing or vaccine
storage characteristics. In this study, it was found that PA6 and PA12 peptides could
remain stable on TMV coat protein by storing purified virus at -20°C. This enabled
animal studies to proceed in spite of these issues. Degradation of peptides displayed on
TMV is a problem that can likely be solved through various mitigation strategies.
Immuno-reactivity of TMV-PA Constructs

Peptides expressed on TMV are cross reactive with antibodies raised against the
native PA83 toxin. The strong signal on western blot between antibodies against native
PA83 and TMV-PA6 coat protein (Figure 5C, Lane 4) show that the PA6 peptide is reactive
even in a linear, denatured state. Reactivity between anti-PA antibodies and the virus
molecules TMV-PA6 and TMV-PA12 in ELISA indicates that PA peptides presented on
a TMV scaffold maintain their ability to directly bind antibodies (Figure 5D). Although
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TMV-PA12 did not react with anti-PA antibodies on western, a signal was detected on
ELISA. This probably has to do with the increased sensitivity of ELISA over
chromogenic western blots. However, it is also possible that the TMV-PA12 peptide may
be presented in a more native conformation in ELISA that enables antibody binding. The
TMV-PA1 molecule was also able to detectably bind anti-PA specific antibodies in the
ELISA format (data not shown). Since the PA1 peptide epitope is derived from the PA20
portion of PA, this molecule was not pursued for vaccine testing in small animals.
Animal vaccination and pathogen challenge studies were pursued for TMV-PA6 and
TMV-PA12 based on their ability to bind antibodies raised against native PA83.
Immunogenicity of TMV-PA Constructs

B. anthracis peptides displayed on TMV induce antibodies in mice that are crossreactive to native PA toxin. TMV-PA6 induced detectable levels of PA specific
antibodies more quickly than TMV-PA12. This observation may be due to the fact that
the PA6 peptide is 16 amino acids in length while the PA12 peptide is only 10. The
additional 6 amino acids on TMV-PA6 probably induces a greater number of reactive B
cell receptors since the 16 amino acid peptide may be comprised of more epitopes than
the 10 amino acid PA12 peptide. This would also explain the higher end-point dilution
titers measured at day 35. It is interesting, however, that these results correlate very
closely with the reactivity of native PA83 antibodies from goats against the TMV-PA
peptide molecules in western blot and ELISA. The goat anti-PA antibody also showed a
lower signal for PA12 compared to PA6 which may not all be attributed to the difference
in peptide size. It is possible that the PA6 epitope is an immunodominant epitope that is
better suited for inducing the immune system in mice and goats. However, human studies
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did not indicate that there were greater levels of antibodies to PA6 compared to PA1278.
Further studies would need to be performed to understand why the PA12 epitope induced
lower levels of antibodies than the PA6 epitope.
End-point dilution titers between TMV-PA6 and TMV-PA12 vaccinated mouse
serum compare well with other published reports utilizing TMV nanoparticle vaccines
using similar routes of administration, dose and injection schedule. Mice vaccinated
subcutaneously, three times over 4 weeks with 50 μg of a TMV molecule displaying a
peptide from Murine Hepatitis Virus developed end-point dilution titers between 1:1,024
and 1:16,384103. This study also used a comparable method for computing end-point
dilution titers in the same order of magnitude (data not shown). These titers are very
similar to those obtained from serum of TMV-PA6 and TMV-PA6/TMV-PA12
intraperitoneally vaccinated mice. Additionally, IgG antibodies to the Murine Hepatitis
Virus peptide peaked at approximately 35-40 days, which is identical to what is reported
here. This is interesting especially since Koo et al. used Monophosphoryl-lipid-A plus
Trehalose dicorynomycolate (MDL+TDM) adjuvant while no adjuvant was used with
TMV-PA vaccines indicating that the TMV carrier molecule acts as a strong adjuvant on
its own.
Most of the antibody response against TMV-PA vaccines was directed to the
TMV carrier molecule as opposed to the surface displayed PA peptide. This indicates that
B cell receptors continue to have access to the TMV coat protein in spite of the surface
displayed PA peptides. It is likely, based on the stability studies mentioned previously,
that the PA peptide undergoes proteolytic cleavage from the TMV surface after injection
into animals. This would enable B cell receptors to gain access to the underlying TMV
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nanoparticle. It is known that TMV rods maintain their structural integrity in serum104.
Therefore, B cell receptors would be mostly limited in their interaction with surface
epitopes on the TMV coat protein. It may be possible to direct more of the antibody
response to the heterologous PA peptides by altering or deleting immunodominant
epitopes on the TMV coat protein surface. This strategy was employed successfully in the
Hepatitis B core VLP platform58. This report shows that deletion of 3 amino acids from
the Hepatitis B core molecule reduced the immunogenicity of the underlying carrier
particle while enhancing the immunogenicity of the displayed B. anthracis PA peptide.
Importantly, this modification led to increased titers of toxin neutralizing antibodies and
protection of LT challenged mice58. TMV nanoparticles can be further optimized for
enhancing immunogenicity of surface displayed foreign peptides for vaccine purposes.
Protective Efficacy of Antibodies Induced by TMV-PA Constructs

Antibodies directed against the PA6 and PA12 specific epitopes, induced by TMV
displaying respective peptide epitopes, are unable to protect mice from anthrax spore
challenge. Furthermore, analysis of the toxin neutralization capacity of the serum
obtained from TMV-PA6, TMV-PA12 and TMV-PA6/TMV-PA12 vaccinated mice is
insufficient at protecting RAW 264.7 cells against LT treatment. These results explain the
low levels of protection observed in C57BL/6J mice after challenge with B. anthracis
spores (Figure 9). These results are in contrast to the report by Crowe et al. that show
antibodies isolated from AVA vaccinated donor serum targeting the PA6 and PA12
epitopes protect 50% and 60% of RAW 264.7 macrophages against LT treatment78. In
addition, PA6 and PA12 directed antibodies protected 30% and 60%, respectively, of A/J
mice against LT challenge78. There are several possibilities for the discrepancies between
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the results in these studies. First, the strain of mice used and the mode of challenge
differed between these studies. Additionally, the PA6 and PA12 specific antibodies were
induced using different antigens and likely differed in class type and affinities. Finally,
the levels of PA6 and PA12 specific antibodies in the blood, between these studies, were
not controlled to match.
Mice strains differ in their sensitivities to anthrax toxin and spores which has an
effect on their survival outcomes. Balb/c mice are among the most sensitive to anthrax
LT while A/J mice and C57BL/6J are moderately resistant105. A 100 ug dose of LT (i.e.
100 ug PA + 100 ug LF) delivered intraperitoneally will kill 95% Balb/c, 55% A/J and
62% of C57BL/6J mice. Interestingly, the same strains of mice show very different
resistance profiles when challenged with non-encapsulated B. anthracis Sterne strain
spores106. A/J mice are among the most sensitive, LD50 = 1.1 x 103 spores, while Balb/c
and C57BL/6J are comparatively more resistant with LD50 values of 6.8 x 107 and 8.6 x
105 spores respectively106. Mice that are more resistant to a specific challenge route are
harder to protect with treatments since higher doses of pathogen are needed to cause
mortality during challenge. From a vaccination standpoint, this means that higher levels
of antibodies need to be induced to neutralize the higher levels of toxin in the blood. In
this study, our use of C57BL/6J mice and a B. anthracis Sterne strain spore challenge
model meant that mice received a high dose of spores (~2.5 x LD100) that continuously
produced multiple waves of toxin. Antibodies in the blood could have been saturated by a
first round of toxin and would need to be produced quickly enough to keep up with LT
production by vegetative B. anthracis in order to provide protection. Crowe et al. used
A/J mice with a single dose of LT at 2.5 x LD50. Protective effects of antibodies were,
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therefore, only required to block an initial wave of LT treatment. Our challenge model is
a step closer to a real world infection model and provides more valid results for
evaluation of experimental vaccines.
Antibody class and avidity play an important role in pathogen neutralization107.
The PA6 and PA12 specific antibodies evaluated between this study and Crowe et al.
were induced using different antigens. Crowe et al. isolated PA6 and PA12 specific
antibodies that were induced by AVA, which is PA83 adsorbed to aluminum hydroxide.
It has been shown that AVA primarily induces IgG1 antibodies108. Although the primary
class of TMV-PA6 and TMV-PA12 induced antibodies was not determined, a study
using TMV to display an influenza HA peptide showed that both IgG1 and IgG2
antibodies were elicited109. This shows that TMV based vaccines are suited for inducing
the appropriate class of antibodies required for B. anthracis toxin neutralization.
However, the AVA vaccine induced PA6 and PA12 antibodies were likely of greater
avidity. The AVA antigen contains PA6 and PA12 epitopes that are in a more native
conformation due to the surrounding amino acids that stabilize these epitopes on the
native PA83 protein. The antibodies induced by the TMV-PA6 and TMV-PA12 vaccines
lack these surrounding amino acids that would likely enable maturation of antibody
species with stronger interactions to the native protein at these regions. Certainly,
differences between the protective efficacies of these antibodies were seen in the RAW
264.7 LT neutralization assay. Antibodies from serum of TMV-PA6, TMV-PA12 and
TMV-PA6/TMV-PA12 mice were not protective against LT treatment of RAW 264.7
macrophages even when PA concentrations were reduced, while Crowe et al. report that
PA6 and PA12 specific antibodies were protective between 50% and 60% respectively78.
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This difference might have to do with the strength at which the PA6 and PA12 specific
antibodies recognized epitopes on the native PA83 toxin.
PA6 and PA12 specific antibody levels in the blood of challenged animals may
have been another contributing factor to failed protection in Stern strain B. anthracis
challenged mice. Crowe et al. injected animals with 30 μg of affinity purified anti-PA6
and anti-PA12 specific antibodies78. This corresponds to a serum concentration before LT
challenge of ~15 μg/mL based on the fact that a 20-25g mouse contains ~2 mL of blood.
This is within the range of antibody levels which can be induced by vaccination110,111.
However, we were unable to measure the antibody levels of PA6 and PA12 induced by
TMV vaccination due to the absence of a comparable standard with known concentration.
It is realistic to assume, however, that 15 ug/mL antibody levels can be achieved against
the PA6 and PA12 specific epitopes.
In conclusion, TMV based vaccination with peptides displayed from PA did not
achieve comparable levels of protection that were reported by Crowe et al. Antibody
levels, avidity, class, animal and challenge model are all factors that may be responsible.
Of all these factors, avidity may likely play a larger role given that antibodies induced by
TMV-PA6 and TMV-PA12 vaccination were shown to bind native PA83 in ELISA but
failed to neutralize LT in RAW 264.7 macrophage toxin neutralization assay even when
PA concentrations were reduced. A more thorough study needs to be performed that
identifies the role each of these factors play in toxin neutralization in order to design
more effective TMV based anthrax vaccines.
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Chapter 6-Future Directions and Conclusion
In summary, this study showed the feasibility of using a plant-virus nanoparticle
as a platform for anthrax vaccines. We successfully expressed 9 of 16 epitopes from the
B. anthracis PA83 toxin that were previously identified as antibody epitopes from AVA
vaccinated donors or functional regions that play important roles in toxin activity. We
discovered that antibodies raised against native PA83 from goats cross-reacted with some
PA peptides displayed on TMV and used this as an initial screening to move forward
with vaccination studies in small animals. TMV-PA6 and TMV-PA12 were selected for
vaccination studies based on this initial screening. We have shown that vaccination with
TMV-PA6 and TMV-PA12 constructs elicited antibodies that were cross-reactive against
native PA83 in ELISA. Using a B. anthracis Sterne strain spore challenge model we
discovered, unfortunately, that these antibodies were insufficient for providing protection
from LT induced mortality. The reason for the failed protection is due to the fact that the
TMV-PA6 and TMV-PA12 induced antibodies are unable to neutralize LT as determined
in a cellular toxin neutralization assay. These results are in contrast to previous reports
that showed that antibodies against these epitopes were, at least, partially protective. A
number of factors may have contributed to these contrasting results and future studies
will need to be performed that might enhance the antibody response of these vaccines
through a more optimal delivery route, possible inclusion of an adjuvant, increased
vaccine dose and/or an improved schedule. Furthermore, more work identifying and
studying epitope-specific antibodies against PA and their characteristics (i.e. affinity,
class, synergistic combinations, etc.) could help evaluate the reasons for the success and
failures of future anthrax vaccine candidates. For instance, this information could be used
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to compare TMV-PA vaccine candidates for their ability to induce antibodies of the
necessary quality to be efficacious.
TMV represents an attractive platform for vaccine development for its ability to
express numerous peptide sequences. It shows promise for vaccines in which short
peptide epitopes that induce highly neutralizing antibodies are sufficient for
neutralization of the toxin or pathogen. PA of B. anthracis is a complex protein that
contains many partially neutralizing antibody epitopes and few fully neutralizing
epitopes. A successful defined epitope focused vaccine would likely require a cocktail of
virus molecules each displaying a different peptide region from PA. This process could
be facilitated using a high-throughput screening of a library of modified TMV coat
protein antigens against mAb cocktails previously identified as providing synergistic
neutralization efficacy. As better protein modeling programs develop, it may be possible
to model conformational antigens, such as the receptor binding loop of PA domain IV, on
the surface of TMV for inducing highly neutralizing, conformationally dependent
antibodies. These advances will one day be feasible but until then we are limited by
experimental methods that will ensure plenty of labor and employ many more future
Ph.D. students.
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PA Antigen VLP/VNP

Production
Host

Animal
Model

Dose

Route

Schedule
(weeks)

Challenge

Survival

Comments

Ref

Hepatitis B
Core

N.tabacum
(Transgenic)

BALB/c
mice

3 μg

IM

0, 2, 4

not performed

n/a

Hepatitis B virus Core did not assemble into VLPs indicating
domain IV interfered with structural characteristics

15

IN

0

not performed

n/a

Influenza virus Assembled Properly and replicated in
embryonated chicken eggs without genetic shift of the PA
domain insert

16

Domain IV

MDCK cells
and
Domain I'
Influenza HA
Embryonated
and IV
Chicken Eggs
Whole PA
complexed
with von
Flock House Trichopulsia ni
Willebrand A
Virus
cells
domain of
CMG2
receptor
Domain IV
or Receptor
Binding
Loop (679693)

Harlan
5.4 or 2.9 μg
Sprague (Double Dose)
SC
Dawley and 10.8 or 5.8
Rats
μg (Single Dose)

Parvovirus
Spodoptera
BALB/c
B19
frugiperda cells
mice

Receptor
Binding
Alfalfa
Loop (679Mosaic Virus
693) of
Domain IV

Domain IV

C57BL/6 5000 pfu/mouse

Rabies Virus
Glycoprotein

2β2-2β3 loop
Hepatitis B
(302-325) of
Core
Domain II

N. tabacum
Samsun NN

BALB/c
mice

BSR cells

Swiss
Webster
Mice

E. coli BL21

Hartley
Guinea
Pigs

13 weeks postvaccination (double
0, 3 (double dose) or 4 weeks postvaccination (single
dose) or 0
(single dose) dose) challenged with
40 μg PA and 8 μg LF
(10 MLDs)

4/4 survivors (double
dose) compared to
No adjuvants used; Multivalent display of PA on VLP surface
1/4 in PA83 control;
shows superiority at inducing a faster and protective immune
5/5 survivors (single
response compared to monovalent PA
dose) compared to
0/5 in PA83 control

54

25 μg

SC

0, 3, 6, 9

not performed

n/a

Immune sera from VLP vaccinated mice showed that
neutralization titers against LT treated RAW 264.7 macrophages
were around 1:400 while rPA immunized mice had
neutralization titers between 1:6400 and 1:12,000

25 μg

IP

0, 2

not performed

n/a

Immune sera from vaccinated mice reacted with PA in western
and ELISA

112

50 μg inactivated
or 3x106
IM
ffu/mouse live
SPBN-D4-E51

0, 3

not performed

n/a

Rabies Virus Glycoprotein displaying domain IV successfully
assembled and formed VLPs, Immune sera from vaccinated
mice was shown to react with PA coated ELISA plates

17

50 μg

IM

0, 2, 4, 8, 12

4/7 survivors (HBcN144-PA-loop2
without adjuvant);
30,000 B. anthracis
3/8 survivors (HBcspores (40 LD50)
N144-PA-loop2 with Hepatitis B virus core assembled into VLPs expressing the 2β2subcutaneously
2β3 loop (302-325 of PA)
adjuvant); 2/3
delivered 2 weeks
survivors (rPA with
after final boost
adjuvant); 1/8
survivors (HBc-N144
with adjuvant)

Table 8 Supplemental: VLP and VNP antigen display platforms for experimental anthrax vaccines. Abbreviations not defined above: HBc (Hepatitis B core),
Plaque forming units (pfu), Foci forming units (ffu).
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55

14,58

Figure 11 Supplemental: pDN15-GFP-6H plasmid map. Shown are the TMV genes necessary for
expressing a heterologous protein (GFP) and the T7 promoter required for producing in vitro transcribed
RNA for direct inoculation of plants. Also shown are the restriction sites KpnI, AvrII and PacI which were
important for producing the pDN15-TCS plasmid. Vector map prepared with ApE plasmid editor.
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Figure 12 Supplemental: pJL Turbo plasmid map. Shown are the genes required for TMV replication and
movement within plant tissue, A. tumefaciens Right and Left Border sequences, 35S promoter for
transcription of TMV RNA in the plant cell nucleus and the multiple cloning site for heterologous gene
expression. Vector map prepared with ApE plasmid editor.
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Figure 13 Supplemental: pDN15-Turbo Cloning Site (TCS) plasmid map. Created through removal of the
1,961 base pair stretch from PacI to KpnI of pDN15-GFP-6H and insertion of the 244 base pair stretch
from pJL Turbo containing the multiple cloning site (PacI, AvrII and NotI) and the TMV CP 3’ UTR.
Compare to pDN15-GFP-6H and pJL Turbo. Insertion of functional coat protein genes at AvrII and NotI
re-enables systemic viral infection of plant hosts. Vector map prepared with ApE plasmid editor.
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Figure 14 Supplemental: Topo-TMV-CP with EcoRV and NotI restriction sites for heterologous peptide
insertions at the C-terminus. Vector map prepared with ApE plasmid editor.
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Figure 15 Supplemental: Topo-TMV-CP with glycine linker (GGGGS x 3) and EcoRV and NotI cloning
sites for heterologous peptide insertions at the C-terminus. Vector map prepared with ApE plasmid editor.

100

Figure 16 Supplemental: Topo-TMV-CP with helical linker (EAAAK x 3) and EcoRV and NotI cloning
sites for heterologous peptide insertions at the C-terminus. Vector map prepared with ApE plasmid editor.
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